10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarter Ended

March 31, 2018

¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number 1-8002

THERMO FISHER SCIENTIFIC INC.

(Exact name of Registrant as specified in its charter)

Delaware	04-2209186
(State of incorporation or organization)	(I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts	02451
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes ý  No o

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes ý  No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ý                                              Accelerated filer o                                       Non-accelerated filer o

Smaller reporting company o                                      Emerging growth company  o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o  No ý

Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the latest practicable date.

Class	Outstanding at March 31, 2018
Common Stock, $1.00 par value	402,323,310

THERMO FISHER SCIENTIFIC INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2018

	TABLE OF CONTENTS
		Page
	PART I
Item 1.	Financial Statements (Unaudited)	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	30
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	37
Item 4.	Controls and Procedures	38
	PART II
Item 1.	Legal Proceedings	38
Item 1A.	Risk Factors	38
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44
Item 6.	Exhibits	44

2

THERMO FISHER SCIENTIFIC INC.

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

CONSOLIDATED BALANCE SHEET

(Unaudited)

	March 31,			December 31,
(In millions except share and per share amounts)	2018			2017
Assets
Current Assets:
Cash and cash equivalents	$	950		$	1,335
Accounts receivable, less allowances of $114 and $109	3,990			3,879
Inventories	2,891			2,971
Refundable income taxes	540			432
Other current assets	1,217			804
Total current assets	9,588			9,421
Property, Plant and Equipment, Net	4,059			4,047
Acquisition-related Intangible Assets, Net	16,393			16,684
Other Assets	1,178			1,227
Goodwill	25,362			25,290
Total Assets	$	56,580		$	56,669
Liabilities and Shareholders' Equity
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	$	2,814		$	2,135
Accounts payable	1,354			1,428
Accrued payroll and employee benefits	643			918
Contract liabilities	909			—
Deferred revenue	—			719
Other accrued expenses	1,352			1,848
Total current liabilities	7,072			7,048
Deferred Income Taxes	2,606			2,766
Other Long-term Liabilities	2,657			2,569
Long-term Obligations	18,122			18,873
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 429,442,440 and 428,327,873 shares issued	429			428
Capital in excess of par value	14,319			14,177
Retained earnings	16,542			15,914
Treasury stock at cost, 27,119,130 and 27,013,311 shares	(3,125		)	(3,103		)
Accumulated other comprehensive items	(2,042		)	(2,003		)
Total shareholders' equity	26,123			25,413
Total Liabilities and Shareholders' Equity	$	56,580		$	56,669

The accompanying notes are an integral part of these consolidated financial statements.

3

THERMO FISHER SCIENTIFIC INC.

CONSOLIDATED STATEMENT OF INCOME

(Unaudited)

	Three Months Ended
	March 31,			April 1,
(In millions except per share amounts)	2018			2017
Revenues
Product revenues	$	4,528		$	4,102
Service revenues	1,325			663
Total revenues	5,853			4,765
Costs and Operating Expenses:
Cost of product revenues	2,325			2,129
Cost of service revenues	948			443
Selling, general and administrative expenses	1,515			1,334
Research and development expenses	234			215
Restructuring and other costs, net	45			24
Total costs and operating expenses	5,067			4,145
Operating Income	786			620
Other Expense, Net	(152		)	(117		)
Income Before Income Taxes	634			503
(Provision for) Benefit from Income Taxes	(55		)	48
Net Income	$	579		$	551
Earnings per Share
Basic	$	1.44		$	1.41
Diluted	$	1.43		$	1.40
Weighted Average Shares
Basic	402			391
Diluted	406			394
Cash Dividends Declared per Common Share	$	0.17		$	0.15

The accompanying notes are an integral part of these consolidated financial statements.

4

THERMO FISHER SCIENTIFIC INC.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(Unaudited)

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Comprehensive Income
Net Income	$	579		$	551
Other Comprehensive Items:
Currency translation adjustment (net of tax benefit of $47 and $0)	47			160
Unrealized gains and losses on available-for-sale investments:
Unrealized holding gains arising during the period (net of tax provision of $0 and $0)	—			1
Unrealized gains and losses on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax benefit of $1 and $1)	2			2
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of ($1) and ($1))	(2		)	(2		)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $1 and $1)	2			2
Total other comprehensive items	49			163
Comprehensive Income	$	628		$	714

The accompanying notes are an integral part of these consolidated financial statements.

5

THERMO FISHER SCIENTIFIC INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Operating Activities
Net income	$	579		$	551
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	575			465
Change in deferred income taxes	(121		)	(127		)
Non-cash stock-based compensation	43			33
Non-cash charges for sale of inventories revalued at the date of acquisition	3			31
Other non-cash expenses, net	24			28
Changes in assets and liabilities, excluding the effects of acquisitions and dispositions:
Accounts receivable	(71		)	(18		)
Inventories	(124		)	(105		)
Other assets	(192		)	(134		)
Accounts payable	(94		)	114
Other liabilities	(520		)	(303		)
Contributions to retirement plans	(24		)	(173		)
Net cash provided by continuing operations	78			362
Net cash used in discontinued operations	—			(1		)
Net cash provided by operating activities	78			361
Investing Activities
Acquisitions, net of cash acquired	(57		)	(301		)
Purchase of property, plant and equipment	(118		)	(93		)
Proceeds from sale of property, plant and equipment	2			1
Other investing activities, net	(6		)	11
Net cash used in investing activities	$	(179	)	$	(382	)

6

THERMO FISHER SCIENTIFIC INC.

CONSOLIDATED STATEMENT OF CASH FLOWS (Continued)

(Unaudited)

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Financing Activities
Net proceeds from issuance of debt	$	—		$	519
Repayment of debt	(453		)	(703		)
Proceeds from issuance of commercial paper	1,306			2,361
Repayments of commercial paper	(1,124		)	(1,795		)
Purchases of company common stock	—			(500		)
Dividends paid	(60		)	(59		)
Net proceeds from issuance of company common stock under employee stock plans	39			58
Other financing activities	(50		)	—
Net cash used in financing activities	(342		)	(119		)
Exchange Rate Effect on Cash	57			66
Decrease in Cash, Cash Equivalents and Restricted Cash	(386		)	(74		)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	1,361			811
Cash, Cash Equivalents and Restricted Cash at End of Period	$	975		$	737
See Note 12 for supplemental cash flow information.

The accompanying notes are an integral part of these consolidated financial statements.

7

THERMO FISHER SCIENTIFIC INC.

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY

(Unaudited)

	Common Stock			Capital in Excess of Par Value		Retained Earnings			Treasury Stock				Accumulated Other Comprehensive Items			Total Shareholders' Equity
(In millions)	Shares	Amount							Shares	Amount
Balance at December 31, 2016	415	$	415	$	12,140	$	13,927		22	$	(2,306	)	$	(2,636	)	$	21,540
Issuance of shares under employees' and directors' stock plans	1	1		79		—			—	(13		)	—			67
Stock-based compensation	—	—		33		—			—	—			—			33
Purchases of company common stock	—	—		—		—			3	(500		)	—			(500		)
Dividends declared	—	—		—		(59		)	—	—			—			(59		)
Net income	—	—		—		551			—	—			—			551
Other comprehensive items	—	—		—		—			—	—			163			163
Balance at April 1, 2017	416	$	416	$	12,252	$	14,419		25	$	(2,819	)	$	(2,473	)	$	21,795
Balance at December 31, 2017	428	$	428	$	14,177	$	15,914		27	$	(3,103	)	$	(2,003	)	$	25,413
Cumulative effect of accounting changes	—	—		—		118			—	—			(88		)	30
Issuance of shares under employees' and directors' stock plans	1	1		72		—			—	(22		)	—			51
Stock-based compensation	—	—		43		—			—	—			—			43
Dividends declared	—	—		—		(69		)	—	—			—			(69		)
Net income	—	—		—		579			—	—			—			579
Other comprehensive items	—	—		—		—			—	—			49			49
Other	—	—		27		—			—	—			—			27
Balance at March 31, 2018	429	$	429	$	14,319	$	16,542		27	$	(3,125	)	$	(2,042	)	$	26,123

The accompanying notes are an integral part of these consolidated financial statements.

8

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.

Interim Financial Statements

The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at March 31, 2018, the results of operations for the three-month periods endedMarch 31, 2018 and April 1, 2017, and the cash flows for the three-month periods endedMarch 31, 2018 and April 1, 2017. Interim results are not necessarily indicative of results for a full year.

The consolidated balance sheet presented as of December 31, 2017, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2017 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC).

Note 1 to the consolidated financial statements for 2017 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. Except for the accounting for revenue arising from contracts with customers as noted below there have been no material changes in the company’s significant accounting policies during the three months ended March 31, 2018.

Revenue Recognition

The company recognizes revenue for the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.

Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (clinical trial logistics, pharmaceutical development and manufacturing services, asset management, diagnostic testing, training, service contracts, and field services including related time and materials) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated as inputs to measure progress. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled to each performance obligation based on relative standalone selling prices and recognizes the related revenue when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.

Payments from customers for most instruments, consumables and services are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g. extended service contracts), upon completion of the service (e.g. pharmaceutical development and manufacturing) or a mix of both.

See Note 3 for revenue disaggregated by type and by geographic region as well as further information about remaining performance obligations.

Contract-related Balances

Contract assets include revenues recognized in advance of billings and are recorded net of estimated losses resulting from the inability to invoice customers. Contract assets are classified as current or noncurrent based on the amount of time expected

9

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

to lapse until the company's right to consideration becomes unconditional. Current contract assets and noncurrent contract assets are included within other current assets and other assets, respectively, in the accompanying balance sheet.

Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet.

Contract asset and liability balances are as follows:

	March 31,		January 1,
(In millions)	2018		2018
Current Contract Assets, Net	$	458	$	396
Current Contract Liabilities	909		805
Noncurrent Contract Liabilities	317		302

Noncurrent contract assets were immaterial in 2018. In the first three months of 2018, the company recognized revenue of $308 million that was included in the contract liabilities balance at January 1,2018.

Warranty Obligations

The liability for warranties is included in other accrued expenses in the accompanying balance sheet.The changes in the carrying amount of standard product warranty obligations are as follows:

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Beginning Balance	$	87		$	78
Provision charged to income	31			25
Usage	(28		)	(25		)
Acquisitions	—			1
Adjustments to previously provided warranties, net	(1		)	(1		)
Currency translation	1			1
Ending Balance	$	90		$	79

Inventories

The components of inventories are as follows:

	March 31,		December 31,
(In millions)	2018		2017
Raw Materials	$	776	$	708
Work in Process	402		505
Finished Goods	1,713		1,758
Inventories	$	2,891	$	2,971

10

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Property, Plant and Equipment

Property, plant and equipment consists of the following:

	March 31,		December 31,
(In millions)	2018		2017
Land	$	405	$	401
Buildings and Improvements	1,688		1,662
Machinery, Equipment and Leasehold Improvements	4,427		4,276
Property, Plant and Equipment, at Cost	6,520		6,339
Less: Accumulated Depreciation and Amortization	2,461		2,292
Property, Plant and Equipment, Net	$	4,059	$	4,047

Acquisition-related Intangible Assets

Acquisition-related intangible assets are as follows:

	Balance at March 31, 2018							Balance at December 31, 2017
(In millions)	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Definite Lived:
Customer relationships	$	17,439	$	(6,170	)	$	11,269	$	17,356	$	(5,902	)	$	11,454
Product technology	6,107		(2,953		)	3,154		6,046		(2,811		)	3,235
Tradenames	1,547		(862		)	685		1,538		(817		)	721
Other	35		(35		)	—		34		(34		)	—
	25,128		(10,020		)	15,108		24,974		(9,564		)	15,410
Indefinite Lived:
Tradenames	1,235		N/A			1,235		1,235		N/A			1,235
In-process research and development	50		N/A			50		39		N/A			39
	1,285		N/A			1,285		1,274		N/A			1,274
Acquisition-related Intangible Assets	$	26,413	$	(10,020	)	$	16,393	$	26,248	$	(9,564	)	$	16,684

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2) and the ultimate loss from abandoning leases at facilities being exited (Note 13). Actual results could differ from those estimates.

Recent Accounting Pronouncements

In February 2018, the FASB issued new guidance to allow reclassifications from accumulated other comprehensive items (AOCI) to retained earnings for certain tax effects on items within AOCI resulting from the Tax Cuts and Jobs Act of 2017 (the Tax Act). The company adopted this guidance in January 2018 and recorded the reclassifications in the period of adoption. The balance sheet impact of adopting this guidance is included in the table below. This guidance only relates to the effects of the

11

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Tax Act. For all other tax law changes that have occurred or may occur in the future, the company reclassifies the tax effects to the consolidated statement of income on an item-by-item basis when the pre-tax item in AOCI is reclassified to income.

In December 2017, the SEC staff issued guidance to address the application of accounting guidance in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act enacted on December 22, 2017. The company reported provisional amounts in its 2017 financial statements for certain income tax effects of the Tax Act for which a reasonable estimate could be determined but for which the accounting impact may change. For example, these estimates may be impacted by the need for further analysis and future clarification and guidance regarding available tax accounting methods and elections, earnings and profits computations and state tax conformity to federal changes. Adjustments to provisional amounts identified during the measurement period, which may be up to December 22, 2018, will be included as adjustments to Benefit from (Provision for) Income Taxes in the period the amounts are determined.

In August 2017, the FASB issued new guidance to simplify the application of hedge accounting guidance. Among other things, the new guidance will permit more hedging strategies to qualify for hedge accounting, allow for additional time to perform an initial assessment of a hedge’s effectiveness, and permit a qualitative effectiveness test for certain hedges after initial qualification. The company adopted this guidance in January 2018. The balance sheet impact of adopting this guidance is included in the table below.

In March 2017, the FASB issued new guidance intended to improve the presentation of net periodic pension cost and net periodic postretirement benefit cost. The new guidance requires the service cost component of net periodic cost be reported in the same line item(s) as other employee compensation costs and all other components of the net periodic cost be reported in the income statement below operating income. The company adopted this guidance on January 1, 2018 and applied the changes to the statement of income retrospectively. As a result of adoption of this guidance, the accompanying 2017 statement of income reflects the following changes from previously reported amounts:

	Three Months Ended
	April 1,
(In millions)	2017
Increase in Total Costs and Operating Expenses (principally Selling, General and Administrative Expenses)	$	2
Decrease in Operating Income	2
Increase in Other Income (Expense)	2

In January 2017, the FASB issued new guidance clarifying the definition of a business and providing criteria to determine when an integrated set of assets and activities is not defined as a business. The new guidance requires such integrated sets to be defined as an asset (and not a business) if substantially all of the fair value of the gross assets acquired or disposed is concentrated in a single identifiable asset or a group of similar identifiable assets. The adoption of this guidance as of January 1, 2018 did not have a material impact on the company’s consolidated financial statements.

In October 2016, the FASB issued new guidance eliminating the deferral of the tax effects of intra-entity asset transfers. The impact of this guidance in future periods will be dependent on the extent of future asset transfers which usually occur in connection with planning around acquisitions and other business structuring activities. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below.

In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. The company plans to adopt the guidance in 2019 using a modified retrospective method. The company is currently evaluating the impact this guidance will have on its consolidated financial statements, however, assets and liabilities will increase upon adoption for right-of-use assets and lease liabilities. The company’s future commitments under lease obligations are summarized in Note 10 to the consolidated financial statements for 2017 included in the company's Annual Report on Form 10-K, filed with the SEC.

In January 2016, the FASB issued new guidance which affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. This guidance requires equity investments to be measured at fair value with subsequent changes recognized in net income, except for those accounted

12

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

for under the equity method or requiring consolidation. The guidance also changes the accounting for investments without a readily determinable fair value and that do not qualify for the practical expedient permitted by the guidance to estimate fair value. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below.

In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most previous revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. During 2016 and 2017, the FASB issued additional guidance and clarification, including the elimination of certain SEC Staff Guidance. The guidance is effective for the company in 2018. The company has elected to adopt this guidance through application of the modified retrospective method by applying it to contracts that were not completed as of December 31, 2017 (in addition to new contracts in 2018).

Adoption of new guidance that became effective on January 1, 2018, impacted the company's Consolidated Balance Sheet as follows:

(In millions)	December 31, 2017 as Reported			Impact of Adopting New Revenue Guidance			Impact of Adopting New Equity Investment Guidance			Impact of Adopting New Intra-entity Tax Guidance			Impact of Adopting New Hedge Accounting Guidance			Impact of Adopting New Tax Effects on Items in AOCI Guidance			January 1, 2018 as Adopted
Accounts Receivable, Less Allowances	$	3,879		$	(8	)	$	—		$	—		$	—		$	—		$	3,871
Inventories	2,971			(252		)	—			—			—			—			2,719
Other Current Assets	804			296			—			—			—			—			1,100
Other Assets	1,227			—			—			(77		)	—			—			1,150
Contract Liabilities	—			805			—			—			—			—			805
Deferred Revenue	719			(719		)	—			—			—			—			—
Other Accrued Expenses	1,848			(153		)	—			—			—			—			1,695
Deferred Income Taxes	2,766			—			—			(57		)	—			2			2,711
Other Long-term Liabilities	2,569			54			—			—			—			—			2,623
Long-term Obligations	18,873			—			—			—			(3		)	—			18,870
Retained Earnings	15,914			49			(1		)	(20		)	3			87			16,032
Accumulated Other Comprehensive Items	(2,003		)	—			1			—			—			(89		)	(2,091		)

Had the company continued to use the revenue recognition guidance in effect prior to 2018, no material changes would have resulted to the consolidated statements of income, comprehensive income, or cash flows for the three months endedMarch 31, 2018, from amounts reported therein. However, inventories would have been $280 million higher and other current assets would have been $344 million lower as of March 31, 2018, primarily as a result of differences in the accounting for pharmaceutical development and manufacturing services under the new revenue guidance. Under the prior guidance, costs of these services were recorded in inventory while under the new guidance, costs are expensed as the manufacturing service is performed and the company's rights to consideration are recorded as contract assets and included in other current assets.

13

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Note 2. Acquisitions

The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.

Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

2018

In 2018, the company acquired, within the Life Sciences Solutions segment, IntegenX Inc., a North America-based provider of a rapid DNA platform for use in forensics and law enforcement applications, for an aggregate purchase price of $65 million.

Note 3. Revenue

Disaggregated Revenue

Revenue by type is as follows:

	Three Months Ended
	March 31,
(In millions)	2018
Revenues
Consumables	$	3,111
Instruments	1,416
Services	1,325
Consolidated revenues	$	5,853

Revenue by geographic region is as follows:

	Three Months Ended
	March 31,
(In millions)	2018
Revenues
North America	$	2,903
Europe	1,518
Asia-Pacific	1,264
Other regions	168
Consolidated revenues	$	5,853

Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See note 4 for revenue by reportable segment and other geographic data.

14

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Remaining Performance Obligations

The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of March 31, 2018 was $4.94 billion. The company will recognize revenue for these performance obligations as they are satisfied, the majority of which is expected to occur within the next twelve months.

Note 4. Business Segment and Geographical Information

The company’s financial performance is reported in four segments. A description of each segment follows.

Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.

Analytical Instruments: provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.

Specialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories.

Laboratory Products and Services: provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial and healthcare settings. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical trials logistics and commercial drug manufacturing.

The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.

15

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Business Segment Information

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Revenues
Life Sciences Solutions	$	1,499		$	1,363
Analytical Instruments	1,257			1,052
Specialty Diagnostics	947			866
Laboratory Products and Services	2,413			1,699
Eliminations	(263		)	(215		)
Consolidated revenues	5,853			4,765
Segment Income (a)
Life Sciences Solutions	517			433
Analytical Instruments	246			192
Specialty Diagnostics	243			233
Laboratory Products and Services	280			216
Subtotal reportable segments (a)	1,286			1,074
Cost of revenues charges	(3		)	(31		)
Selling, general and administrative charges, net	(8		)	(31		)
Restructuring and other costs, net	(45		)	(24		)
Amortization of acquisition-related intangible assets	(444		)	(368		)
Consolidated operating income	786			620
Other expense, net (b)	(152		)	(117		)
Income from continuing operations before income taxes	$	634		$	503
Depreciation
Life Sciences Solutions	$	31		$	33
Analytical Instruments	18			17
Specialty Diagnostics	19			17
Laboratory Products and Services	63			30
Consolidated depreciation	$	131		$	97

(a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

(b) The company does not allocate other expense, net to its segments.

16

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Geographical Information

	Three Months Ended
	March 31,		April 1,
(In millions)	2018		2017
Revenues (c)
United States	$	2,756	$	2,377
China	541		441
Other	2,556		1,947
Consolidated revenues	$	5,853	$	4,765

(c) Revenues are attributed to countries based on customer location.

Note 5. Other Expense, Net

The components of other expense, net, in the accompanying statement of income are as follows:

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Interest Income	$	20		$	18
Interest Expense	(163		)	(135		)
Other Items, Net	(9		)	—
Other Expense, Net	$	(152	)	$	(117	)

Other Items, Net

In all periods, other items, net includes currency transaction gains and losses on monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income.

17

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Note 6. Income Taxes

The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following:

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Statutory Federal Income Tax Rate	21		%	35		%
Provision for Income Taxes at Statutory Rate	$	133		$	176
Increases (Decreases) Resulting From:
Foreign rate differential	(19		)	(84		)
Income tax credits	(41		)	(41		)
Foreign-derived intangible income	(9		)	—
Singapore tax holiday	(8		)	(5		)
Impact of change in tax laws and apportionment on deferred taxes	3			(63		)
Transition tax and other initial impacts of U.S. tax reform	70			—
Provision of tax reserves, net	(49		)	—
Excess tax benefits from stock options and restricted stock units	(25		)	(24		)
Other, net	—			(7		)
Provision for (benefit from) income taxes	$	55		$	(48	)

The company has operations and a taxable presence in approximately 50 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries.

In the first quarter of 2018, the company recorded a net tax provision of $21 million to adjust the estimated initial impacts of U.S. tax reform recorded in 2017, consisting of an incremental provision of $70 million offset in part by a $49 million reduction of related unrecognized tax benefits established in 2017. The adjustment was required based on new U.S. Treasury guidance released in the first quarter of 2018.

The company has significant activities in Singapore and has received considerable tax incentives. The local taxing authority granted the company pioneer company status which provides an incentive encouraging companies to undertake activities that have the effect of promoting economic or technological development in Singapore. This incentive equates to a tax exemption on earnings associated with most of the company’s manufacturing activities in Singapore and continues through December 31, 2026. In 2018 and 2017, the impact of this tax holiday decreased the annual effective tax rates by 1.3 percentage points and 0.9 percentage point, respectively, and increased diluted earnings per share by approximately $0.02 and $0.01, respectively.

Unrecognized Tax Benefits

As of March 31, 2018, the company had $1.27 billion of unrecognized tax benefits which, if recognized, would reduce the effective tax rate.

18

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:

(In millions)	2018
Balance at beginning of year	$	1,409
Reductions due to acquisitions	(9		)
Additions for tax positions of current year	1
Additions for tax positions of prior years	1
Reductions for tax positions of prior years	(84		)
Settlements	(45		)
Balance at end of period	$	1,273

Note 7. Earnings per Share

	Three Months Ended
	March 31,		April 1,
(In millions except per share amounts)	2018		2017
Net Income	$	579	$	551
Basic Weighted Average Shares	402		391
Plus Effect of:
Stock options and restricted units	4		3
Diluted Weighted Average Shares	406		394
Basic Earnings per Share	$	1.44	$	1.41
Diluted Earnings per Share	$	1.43	$	1.40
Antidilutive Stock Options Excluded from Diluted Weighted Average Shares	2		3

19

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Note 8. Debt and Other Financing Arrangements

	Effective Interest Rate at March 31,		March 31,			December 31,
(Dollars in millions)	2018		2018			2017
Commercial Paper	—	%	$	1,171		$	960
Floating Rate 2-Year Senior Notes, Due 8/9/2018 (euro-denominated)	0.38	%	739			721
2.15% 3-Year Senior Notes, Due 12/14/2018			—			450
2.40% 5-Year Senior Notes, Due 2/1/2019	2.59	%	900			900
Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated)	0.09	%	616			600
6.00% 10-Year Senior Notes, Due 3/1/2020	2.97	%	750			750
4.70% 10-Year Senior Notes, Due 5/1/2020	4.23	%	300			300
1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated)	1.62	%	524			510
5.00% 10-Year Senior Notes, Due 1/15/2021	3.24	%	400			400
4.50% 10-Year Senior Notes, Due 3/1/2021	6.24	%	1,000			1,000
3.60% 10-Year Senior Notes, Due 8/15/2021	6.06	%	1,100			1,100
3.30% 7-Year Senior Notes, Due 2/15/2022	3.43	%	800			800
2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated)	2.28	%	616			600
3.15% 10-Year Senior Notes, Due 1/15/2023	3.30	%	800			800
3.00% 7-Year Senior Notes, Due 4/15/2023	6.23	%	1,000			1,000
4.15% 10-Year Senior Notes, Due 2/1/2024	4.16	%	1,000			1,000
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)	0.95	%	1,232			1,201
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)	2.10	%	789			768
3.65% 10-Year Senior Notes, Due 12/15/2025	3.77	%	350			350
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)	1.53	%	863			840
2.95% 10-Year Senior Notes, Due 9/19/2026	3.19	%	1,200			1,200
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)	1.67	%	616			600
3.20% 10-Year Senior Notes, Due 8/15/2027	3.39	%	750			750
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)	1.46	%	739			721
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)	2.08	%	863			840
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)	2.94	%	863			840
5.30% 30-Year Senior Notes, Due 2/1/2044	5.37	%	400			400
4.10% 30-Year Senior Notes, Due 8/15/2047	4.32	%	750			750
Other			23			24
Total Borrowings at Par Value			21,154			21,175
Fair Value Hedge Accounting Adjustments			(120		)	(70		)
Unamortized Discount, Net			(8		)	(2		)
Unamortized Debt Issuance Costs			(90		)	(95		)
Total Borrowings at Carrying Value			20,936			21,008
Less: Short-term Obligations and Current Maturities			2,814			2,135
Long-term Obligations			$	18,122		$	18,873

The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium, the amortization of any debt issuance costs and, if applicable, adjustments related to hedging.

See Note 11 for fair value information pertaining to the company’s long-term obligations.

Credit Facilities

The company has a revolving credit facility with a bank group that provides for up to $2.50 billion of unsecured multi-currency revolving credit. The facility expires in July 2021. The agreement calls for interest at either a LIBOR-based rate, a

20

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

EURIBOR-based rate (for funds drawn in Euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in our revolving credit facility (the Facility) include a Consolidated Leverage Ratio (total debt-to-Consolidated EBITDA) and a Consolidated Interest Coverage Ratio (Consolidated EBITDA to Consolidated Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a maximum Consolidated Leverage Ratio of 4.0:1.0 through the second quarter of 2018 and then stepping down to 3.5:1.0 for the third quarter of 2018 and thereafter. The company has also agreed that so long as any lender has any commitment under the Facility or any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.0:1.0 as of the last day of any fiscal quarter. As of March 31, 2018, no borrowings were outstanding under the Facility, although available capacity was reduced by approximately $75 million as a result of outstanding letters of credit.

Commercial Paper Programs

The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of March 31, 2018, outstanding borrowings under these programs were $1.17 billion, with a weighted average remaining period to maturity of 50 days and are classified as short-term obligations in the accompanying balance sheet.

Senior Notes

Interest on the floating rate senior notes is payable quarterly. Interest is payable annually on the other euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements.

Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the company issued the Floating Rate Senior Notes due 2018 included in the table above. This subsidiary has no independent function other than financing activities. The Floating Rate Senior Notes due 2018 are fully and unconditionally guaranteed by the company and no other subsidiaries of the company have guaranteed the obligations.

Interest Rate Swap Arrangements

The company has entered into LIBOR-based interest rate swap arrangements with various banks on several of its outstanding senior notes. The aggregate amounts of the swaps are equal to the principal amounts of the notes and the payment dates of the swaps coincide with the interest payment dates of the notes. The swap contracts provide for the company to pay a variable interest rate and receive a fixed rate. The variable interest rates reset monthly. The swaps have been accounted for as fair value hedges of the notes. See Note 11 for additional information. The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at March 31, 2018:

	Aggregate Notional Amount		Pay Rate as of
(Dollars in millions)		Pay Rate	March 31, 2018		Receive Rate
4.50% Senior Notes due 2021	1,000	1-month LIBOR + 3.4420%	5.1062	%	4.50	%
3.60% Senior Notes due 2021	1,100	1-month LIBOR + 2.5150%	4.2916	%	3.60	%
3.00% Senior Notes due 2023	1,000	1-month LIBOR + 1.7640%	3.5406	%	3.00	%

21

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Note 9. Commitments and Contingencies

Environmental Matters

The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At March 31, 2018, the company’s total environmental liability was approximately $61 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows.

Litigation and Related Contingencies

There are various lawsuits and claims pending against the company including matters involving product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below or in the company's 2017 financial statements and notes included in the company's Annual Report on Form 10-K filed with the SEC, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows.

Product Liability, Workers Compensation and Other Personal Injury Matters

For product liability, workers compensation and other personal injury matters, the company accrues the most likely amount or at least the minimum of the range of possible loss when a range of possible loss can be estimated. The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.

Intellectual Property Matters

On May 26, 2010, Promega Corp. & Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften EV filed a complaint against Life Technologies in the United States District Court for the Western District of Wisconsin. The plaintiffs allege patent infringement by sales and uses of Applied Biosystems’ short tandem repeat DNA identification products outside the scope of a

22

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

2006 license agreement. The plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief. Although a jury initially found willful infringement and assessed damages at $52 million the District Court subsequently overturned the verdict on the grounds that the plaintiff had failed to prove infringement. The District Court entered judgment in favor of Life Technologies; and plaintiffs and Life Technologies filed cross-appeals with the United States Court of Appeals for the Federal Circuit. The $52 million award was accrued by Life Technologies and the liability was assumed by the company as of the date of the acquisition. On December 15, 2014, the Court of Appeals issued a decision invalidating four of the plaintiffs’ patents, but finding infringement by Life Technologies of the remaining fifth patent. The Court of Appeals also ordered a new trial on damages in the District Court. Life Technologies' petition to the U.S. Supreme Court seeking review of the Court of Appeals’ judgment was granted on June 27, 2016, and the case was stayed in the District Court pending the outcome of the Supreme Court’s review. On February 22, 2017, the Supreme Court issued a decision reversing the Court of Appeals’ judgment and remanding the case to the Court of Appeals for further proceedings in view of the Supreme Court’s legal interpretation of the patent law statute in question. On November 13, 2017, the Court of Appeals issued a decision holding that Promega is not entitled to recover any damages and affirming the District Court’s grant of judgment in favor of Life Technologies and denial of Promega’s motion for a new trial. The Court of Appeals denied Promega’s petition for rehearing on February 14, 2018, and Promega has 90 days therefrom to file a petition with the U.S. Supreme Court seeking review of the Court of Appeals' decision. The company has maintained the $52 million accrual, pending conclusion of this matter.

On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product "supply centers" installed at customer sites. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief. On August 24, 2017, Unisone filed an appeal from a decision by the Patent Trial and Appeal Board that found the challenged patent claims invalid.

Note 10. Comprehensive Income and Shareholders' Equity

Comprehensive Income (Loss)

Comprehensive income (loss) combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet.

Changes in each component of accumulated other comprehensive items, net of tax are as follows: 

(In millions)	Currency Translation Adjustment			Unrealized Losses on Available-for- Sale Investments			Unrealized Losses on Hedging Instruments			Pension and Other Postretirement Benefit Liability Adjustment			Total
Balance at December 31, 2017	$	(1,755	)	$	(1	)	$	(50	)	$	(197	)	$	(2,003	)
Cumulative effect of accounting changes (Note 1)	(54		)	1			(11		)	(24		)	(88		)
Other comprehensive income (loss) before reclassifications	47			—			—			(2		)	45
Amounts reclassified from accumulated other comprehensive items	—			—			2			2			4
Net other comprehensive items	47			—			2			—			49
Balance at March 31, 2018	$	(1,762	)	$	—		$	(59	)	$	(221	)	$	(2,042	)

23

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Note 11. Fair Value Measurements and Fair Value of Financial Instruments

Fair Value Measurements

The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2018. The company’s financial assets and liabilities carried at fair value are primarily comprised of insurance contracts, investments in money market funds, derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.

Level 3: Inputs are unobservable data points that are not corroborated by market data.

The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2018 and December 31, 2017:

	March 31,		Quoted Prices in Active Markets		Significant Other Observable  Inputs		Significant Unobservable Inputs
(In millions)	2018		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	36	$	36	$	—	$	—
Bank time deposits	2		2		—		—
Investments in mutual funds and other similar instruments	13		13		—		—
Warrants	2		—		2		—
Insurance contracts	115		—		115		—
Derivative contracts	7		—		7		—
Total Assets	$	175	$	51	$	124	$	—
Liabilities
Derivative contracts	$	165	$	—	$	165	$	—
Contingent consideration	41		—		—		41
Total Liabilities	$	206	$	—	$	165	$	41

24

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

	December 31,		Quoted Prices in  Active Markets		Significant Other Observable  Inputs		Significant  Unobservable  Inputs
(In millions)	2017		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	22	$	22	$	—	$	—
Bank time deposits	2		2		—		—
Investments in mutual funds and other similar instruments	13		13		—		—
Warrants	2		—		2		—
Insurance contracts	116		—		116		—
Derivative contracts	10		—		10		—
Total Assets	$	165	$	37	$	128	$	—
Liabilities
Derivative contracts	$	139	$	—	$	139	$	—
Contingent consideration	35		—		—		35
Total Liabilities	$	174	$	—	$	139	$	35

The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determines the fair value of acquisition-related contingent consideration based on the probability-weighted discounted cash flows associated with such future payments. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration.

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Contingent Consideration
Beginning Balance	$	35		$	6
Acquisitions	11			9
Payments	(5		)	—
Change in fair value included in earnings	—			25
Ending Balance	$	41		$	40

Derivative Contracts

As of both March 31, 2018 and December 31, 2017, the total notional amount of outstanding interest rate swaps was $3.10 billion. These swap arrangements are described in Note 8. The notional amounts of currency exchange contracts outstanding totaled $2.98 billion and $2.92 billion at March 31, 2018 and December 31, 2017, respectively.

25

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income.

	Fair Value – Assets				Fair Value – Liabilities
	March 31,		December 31,		March 31,		December 31,
(In millions)	2018		2017		2018		2017
Derivatives Designated as Hedging Instruments
Interest rate swaps (a)	$	—	$	—	$	162	$	124
Derivatives Not Designated as Hedging Instruments
Currency exchange contracts (b)	7		10		3		15
Total Derivatives	$	7	$	10	$	165	$	139

(a) The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities.

(b) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses.

The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations:

	Carrying Amount of the Hedged Liability				Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability (c)
	March 31,		December 31,		March 31,			December 31,
(In millions)	2018		2017		2018			2017
Long-term Obligations	$	3,261	$	3,309	$	(120	)	$	(70	)

(c) Includes increases in the carrying amount of $40 million and $43 million at March 31, 2018 and December 31, 2017, respectively, on discontinued hedging relationships.

	Gain (Loss) Recognized
	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Fair Value Hedging Relationships
Interest rate swaps
Hedged long-term obligations - included in other expense, net	$	(38	)	$	(6	)
Derivatives designated as hedging instruments - included in other expense, net	42			3
Derivatives Designated as Cash Flow Hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to other expense, net	(3		)	(3		)
Derivatives Designated as Net Investment Hedges
Foreign currency-denominated debt
Included in currency translation adjustment within other comprehensive items	(200		)	(46		)
Derivatives Not Designated as Hedging Instruments
Currency exchange contracts
Included in cost of revenues	(2		)	(1		)
Included in other expense, net	(8		)	19

26

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.

The company uses foreign currency-denominated debt to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The company’s euro-denominated senior notes have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in currency translation adjustment within other comprehensive items and shareholders’ equity.

See Note 1 to the consolidated financial statements for 2017 included in the company's Annual Report on Form 10-K for additional information on the company's risk management objectives and strategies.

Fair Value of Other Financial Instruments

The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:

	March 31, 2018				December 31, 2017
	Carrying		Fair		Carrying		Fair
(In millions)	Value		Value		Value		Value
Notes Receivable	$	94	$	99	$	89	$	93
Debt Obligations:
Senior notes	$	19,742	$	20,053	$	20,024	$	20,639
Commercial paper	1,171		1,171		960		960
Other	23		23		24		24
	$	20,936	$	21,247	$	21,008	$	21,623

The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Note 12. Supplemental Cash Flow Information

	Three Months Ended
	March 31,		April 1,
(In millions)	2018		2017
Non-cash Investing and Financing Activities
Declared but unpaid dividends	$	69	$	60
Issuance of stock upon vesting of restricted stock units	61		34

27

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:

	March 31,		December 31,
(In millions)	2018		2017
Cash and Cash Equivalents	$	950	$	1,335
Restricted Cash Included in Other Current Assets	23		24
Restricted Cash Included in Other Assets	2		2
Cash, Cash Equivalents and Restricted Cash	$	975	$	1,361

Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

Note 13. Restructuring and Other Costs, Net

Restructuring and other costs in the first three months of 2018 included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S. and Europe; third-party transaction/integration costs related to the acquisition of Patheon; sales of inventories revalued at the date of acquisition; and net charges for litigation matters. In the first three months of 2018, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.

As of May 4, 2018, the company has identified restructuring actions that will result in additional charges of approximately $105 million, primarily in 2018 and 2019, which will be recorded when specified criteria are met, such as communication of benefit arrangements and abandonment of leased facilities.

First Quarter of 2018

During the first quarter of 2018, the company recorded net restructuring and other costs by segment as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs, Net		Total
Life Sciences Solutions	$	—	$	—	$	13	$	13
Analytical Instruments	—		—		17		17
Specialty Diagnostics	—		—		4		4
Laboratory Products and Services	3		7		10		20
Corporate	—		1		1		2
	$	3	$	8	$	45	$	56

The principal components of net restructuring and other costs by segment are as follows:

Life Sciences Solutions

In the first quarter of 2018, the Life Sciences Solutions segment recorded $13 million of net restructuring and other charges, principally charges for litigation-related matters and severance due to employees of an acquired business at the date of acquisition.

Analytical Instruments

In the first quarter of 2018, the Analytical Instruments segment recorded $17 million of net restructuring and other charges, primarily abandoned facilities costs associated with the remediation and closure of a manufacturing facility in the U.S.

28

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Specialty Diagnostics

In the first quarter of 2018, the Specialty Diagnostics segment recorded $4 million of net restructuring and other charges for severance and other costs associated with facility consolidations in the U.S. and Europe.

Laboratory Products and Services

In the first quarter of 2018, the Laboratory Products and Services segment recorded $20 million of net restructuring and other charges. The segment recorded $3 million of charges to cost of revenues for sales of inventories revalued at the date of acquisition, as well as $7 million of charges to selling, general, and administrative expenses for third-party transaction/integration costs related to the acquisition of Patheon. The segment also recorded $10 million of restructuring and other costs, primarily for employee severance, as well as hurricane response costs.

Corporate

In the first quarter of 2018, the company's corporate operations recorded $2 million of net restructuring and other charges primarily for severance.

The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.

(In millions)	Severance			Abandonment of Excess Facilities			Other (a)			Total
Balance at December 31, 2017	$	30		$	40		$	6		$	76
Costs incurred in 2018 (c)	19			16			4			39
Reserves reversed (b)	(3		)	(1		)	—			(4		)
Payments	(10		)	(8		)	(5		)	(23		)
Balance at March 31, 2018	$	36		$	47		$	5		$	88

(a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

(b) Represents reductions in cost of plans.

(c) Excludes $10 million of charges, net, primarily associated with litigation-related matters, hurricane response costs, and non-cash compensation due at an acquired business.

The company expects to pay accrued restructuring costs as follows: severance, employee-retention obligations and other costs, primarily through 2018; and abandoned-facility payments, over lease terms expiring through 2027.

29

THERMO FISHER SCIENTIFIC INC.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 are made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Thermo Fisher intends or believes will or may occur in the future. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this Quarterly Report.

A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed under the heading "Risk Factors" in Part II, Item 1A of this report on Form 10-Q.

Overview

The company develops, manufactures and sells a broad range of products that are sold worldwide. The company expands the product lines and services it offers by developing and commercializing its own technologies and by making strategic acquisitions of complementary businesses. The company’s continuing operations fall into four business segments (see Note 4): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Services.

Recent Acquisitions

The company’s strategy is to augment internal growth at existing businesses with complementary acquisitions. The company’s principal recent acquisitions and divestitures are described below.

On February 14, 2017, the company acquired, within the Life Sciences Solutions segment, Finesse Solutions, Inc., a North America-based developer of scalable control automation systems and software for bioproduction, for a total purchase price of $221 million, net of cash acquired. The acquisition expanded the company's bioproduction offerings. Revenues of Finesse Solutions were approximately $50 million in 2016.

On March 2, 2017, the company acquired, within the Analytical Instruments segment, Core Informatics, a North America-based provider of cloud-based platforms supporting scientific data management, for a total purchase price of $94 million, net of cash acquired. The acquisition enhanced the company's existing informatics solutions. Revenues of Core Informatics were approximately $10 million in 2016.

On August 29, 2017, the company acquired, within the Laboratory Products and Services segment, substantially all of the issued and outstanding shares of Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, for $35.00 per share in cash, or $7.36 billion, including the assumption of net debt. The company financed the purchase price, including the repayment of indebtedness of Patheon, with issuances of debt and equity.

Patheon provides comprehensive, integrated and highly customizable solutions as well as the expertise to help biopharmaceutical companies of all sizes satisfy complex development and manufacturing needs. The acquisition provided entry into the pharmaceutical contract development and manufacturing organization market and added a complementary service to the company's existing pharmaceutical services portfolio. Patheon's revenues totaled $1.87 billion for the year ended October 31, 2016.

30

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Overview of Results of Operations and Liquidity

	Three Months Ended
	March 31,					April 1,
(Dollars in millions)	2018					2017
Revenues
Life Sciences Solutions	$	1,499		25.6	%	$	1,363		28.6	%
Analytical Instruments	1,257			21.5	%	1,052			22.1	%
Specialty Diagnostics	947			16.2	%	866			18.2	%
Laboratory Products and Services	2,413			41.2	%	1,699			35.7	%
Eliminations	(263		)	(4.5	)%	(215		)	(4.6	)%
	$	5,853		100	%	$	4,765		100	%

Sales in the first quarter of 2018 were $5.85 billion, an increase of $1.09 billion from 2017. Sales increased$565 million due to acquisitions. The favorable effects of currency translation resulted in an increase in revenues of $209 million in the first quarter of 2018. Aside from the effects of acquisitions and currency translation, revenues increased$314 million (7%) primarily due to increased demand in the quarter compared to the 2017 quarter. Sales to customers in each of the company's primary end markets grew. Sales growth was moderate in North America, strong in Europe and particularly strong in Asia.

In the first quarter of 2018, total company operating income and operating income margin were $786 million and 13.4%, respectively, compared with $620 million and 13.0%, respectively, in 2017. The increase in operating income was primarily due to profit on higher sales in local currencies and, to a lesser extent, the effect of acquisitions and productivity improvements, net of inflationary cost increases, offset in part by an increase in amortization of acquisition-related intangible assets, due to recent acquisitions, and strategic growth investments.The company’s references to strategic growth investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, focused research projects and other expenditures to enhance the customer experience. The company’s references throughout this discussion to productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system, reduced costs resulting from global sourcing initiatives, a lower cost structure following restructuring actions, including headcount reductions and consolidation of facilities, and low cost region manufacturing.

The company recorded a $55 million provision for income taxes in the first quarter of 2018. In the first quarter of 2018, the company recorded a net tax provision of $21 million to adjust the estimated initial impacts of U.S. tax reform recorded in 2017, consisting of an incremental provision of $70 million offset in part by a $49 million reduction of related unrecognized tax benefits established in 2017. The adjustment was required based on new U.S. Treasury guidance released in the first quarter of 2018. The company expects its effective tax rate for all of 2018 will be between 6% and 9% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting purposes and are expected to total $525 to $575 million in 2018.

The company recorded a $48 million benefit from income taxes in the first quarter of 2017 as a result of a $65 million favorable adjustment to deferred tax balances due to extension of a tax holiday agreement in Singapore. The effective rate in both periods was also affected by relatively significant earnings in lower tax jurisdictions.

Net income increased to $579 million in the first quarter of 2018 from $551 million in the first quarter of 2017, primarily due to the increase in operating income in the 2018 period (discussed above) offset in part by higher income taxes (discussed above) and, to a lesser extent, higher interest expense due to an increase in outstanding debt.

During the first three months of 2018, the company’s cash flow from operations totaled $78 million compared with $361 million for 2017. The decrease primarily resulted from higher investment in working capital in 2018, offset in part by higher income before amortization and depreciation in the 2018 period.

As of March 31, 2018, the company’s short-term debt totaled $2.81 billion including $1.17 billion of commercial paper obligations and $1.64 billion of senior notes due within the next twelve months. The company has a revolving credit facility with a bank group that provides up to $2.50 billion of unsecured multi-currency revolving credit. If the company borrows under

31

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Overview of Results of Operations and Liquidity (continued)

this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of March 31, 2018, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by approximately $75 million as a result of outstanding letters of credit.

The company believes that its existing cash and cash equivalents of $950 million as of March 31, 2018 and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.

Critical Accounting Policies and Estimates

The company’s discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosure of contingent liabilities. On an on-going basis, management evaluates its estimates, including those related to business combinations, intangible assets and goodwill, income taxes, contingencies and litigation, and pension costs. Management believes the most complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to make estimates about the effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and economic conditions and other assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the carrying value of assets and liabilities where the values are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Form 10-K for 2017, describe the significant accounting estimates and policies used in preparation of the consolidated financial statements. While there have been no significant changes in the company's critical accounting policies during the first three months of 2018, as described in Note 1, the company changed the manner in which it accounts for revenue from contracts with customers under guidance that became effective January 1, 2018.

Results of Operations

First Quarter2018 Compared With First Quarter2017

	Three Months Ended
(In millions)	March 31, 2018			April 1, 2017			Total Change			Currency Translation			Acquisitions/ Divestitures			Operations
Revenues
Life Sciences Solutions	$	1,499		$	1,363		$	136		$	62		$	—		$	74
Analytical Instruments	1,257			1,052			205			54			12			139
Specialty Diagnostics	947			866			81			38			3			40
Laboratory Products and Services	2,413			1,699			714			62			554			98
Eliminations	(263		)	(215		)	(48		)	(7		)	(4		)	(37		)
Consolidated Revenues	$	5,853		$	4,765		$	1,088		$	209		$	565		$	314

Sales in the first quarter of 2018 were $5.85 billion, an increase of $1.09 billion from the first quarter of 2017. Sales increased$565 million due to acquisitions. The favorable effects of currency translation resulted in an increase in revenues of $209 million in 2018. Aside from the effects of acquisitions/divestitures and currency translation, revenues increased$314 million (7%) primarily due to increased demand in the quarter compared to the 2017 quarter. Sales to customers in each of the company's primary end markets grew. Sales growth was moderate in North America, strong in Europe and particularly strong in Asia.

In the first quarter of 2018, total company operating income and operating income margin were $786 million and 13.4%, respectively, compared with $620 million and 13.0%, respectively, in 2017. The increase in operating income was primarily due to profit on higher sales in local currencies and, to a lesser extent, the effect of acquisitions and productivity improvements, net of inflationary cost increases, offset in part by an increase in amortization of acquisition-related intangible assets, due to recent acquisitions, and strategic growth investments.

32

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

In the first quarter of 2018, the company recorded restructuring and other costs, net, of $56 million, including $3 million of charges to cost of revenues primarily for the sale of inventories revalued at the date of acquisition. The company recorded $8 million of charges to selling, general and administrative expenses, primarily for third-party transaction/integration costs related to the acquisition of Patheon. The company recorded $35 million of cash restructuring costs, including severance and abandoned facilities costs associated with the closure and consolidation of facilities in the U.S. and Europe. The company also recorded $10 million of other charges, net, principally for litigation-related matters and hurricane response costs (see Note 13).

In the first quarter of 2017, the company recorded restructuring and other costs, net, of $86 million, including $31 million of charges to cost of revenues primarily for the sale of inventories revalued at the date of acquisition and $31 million of charges to selling, general and administrative expenses, primarily for changes in estimates of acquisition contingent consideration. In addition, the company recorded $18 million of cash restructuring costs, primarily to achieve acquisition synergies, including severance and abandoned facilities costs associated with the closure and consolidation of facilities in the U.S. The company’s other businesses incurred costs for continued headcount reductions and facility consolidations in an effort to streamline operations including severance at several businesses and abandoned facility expenses at businesses that have been or are being consolidated in the U.S., Europe and Asia. The company also recorded $5 million of other charges, net, principally associated with litigation-related matters.

As of May 4, 2018, the company has identified restructuring actions that will result in additional charges of approximately $105 million in 2018 and 2019, and expects to identify additional actions during 2018 which will be recorded when specified criteria are met, such as communication of benefit arrangements and abandonment of leased facilities.

Segment Results

The company’s management evaluates segment operating performance using operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition-related activities; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitate comparison of performance for determining compensation (Note 4). Accordingly, the following segment data is reported on this basis.

33

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

	Three Months Ended
	March 31,			April 1,
(Dollars in millions)	2018			2017			Change
Revenues
Life Sciences Solutions	$	1,499		$	1,363		10	%
Analytical Instruments	1,257			1,052			19	%
Specialty Diagnostics	947			866			9	%
Laboratory Products and Services	2,413			1,699			42	%
Eliminations	(263		)	(215		)	22	%
Consolidated Revenues	$	5,853		$	4,765		23	%
Segment Income
Life Sciences Solutions	$	517		$	433		19	%
Analytical Instruments	246			192			28	%
Specialty Diagnostics	243			233			4	%
Laboratory Products and Services	280			216			30	%
Subtotal Reportable Segments	1,286			1,074			20	%
Cost of Revenues Charges	(3		)	(31		)
Selling, General and Administrative Charges, Net	(8		)	(31		)
Restructuring and Other Costs, Net	(45		)	(24		)
Amortization of Acquisition-related Intangible Assets	(444		)	(368		)
Consolidated Operating Income	$	786		$	620		27	%
Reportable Segments Operating Income Margin	22.0		%	22.5		%
Consolidated Operating Income Margin	13.4		%	13.0		%

Income from the company’s reportable segments increased 20% to $1.29 billion in the first quarter of 2018 due primarily to profit on higher sales in local currencies and, to a lesser extent, the effect of acquisitions, favorable foreign currency exchange and productivity improvements, net of inflationary cost increases, offset in part by strategic growth investments.

Life Sciences Solutions

	Three Months Ended
	March 31,			April 1,
(Dollars in millions)	2018			2017			Change
Revenues	$	1,499		$	1,363		10	%
Operating Income Margin	34.5		%	31.8		%	2.7 pt

Sales in the Life Sciences Solutions segment increased$136 million to $1.50 billion in the first quarter of 2018. Sales increased $74 million (5%) due to higher revenues at existing businesses and $62 million due to the favorable effects of currency translation. The increase in revenue at existing businesses was primarily due to increased demand for biosciences products and bioprocess production products.

Operating income margin was 34.5% in the first quarter of 2018 compared to 31.8% in the first quarter of 2017. The increase resulted primarily from productivity improvements, net of inflationary cost increases, profit on higher sales in local currencies and favorable foreign currency exchange. These increases were offset in part by unfavorable sales mix.

34

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

Analytical Instruments

	Three Months Ended
	March 31,			April 1,
(Dollars in millions)	2018			2017			Change
Revenues	$	1,257		$	1,052		19	%
Operating Income Margin	19.6		%	18.2		%	1.4 pt

Sales in the Analytical Instruments segment increased$205 million to $1.26 billion in the first quarter of 2018. Sales increased$139 million (13%) due to higher revenues at existing businesses, $54 million due to the favorable effects of currency translation and $12 million due to acquisitions. The increase in revenue at existing businesses was due to increased demand at each of the segment's principal businesses, particularly for products sold by the segment's electron microscopy business and chromatography and mass spectrometry business.

Operating income margin was 19.6% in the first quarter of 2018 compared to 18.2% in the first quarter of 2017. The increase resulted primarily from profit on higher sales in local currencies and, to a lesser extent, productivity improvements, net of inflationary cost increases, offset in part by strategic growth investments and, to a lesser extent, unfavorable foreign currency exchange.

Specialty Diagnostics

	Three Months Ended
	March 31,			April 1,
(Dollars in millions)	2018			2017			Change
Revenues	$	947		$	866		9	%
Operating Income Margin	25.6		%	26.9		%	-1.3 pt

Sales in the Specialty Diagnostics segment increased$81 million to $947 million in the first quarter of 2018. Sales increased$40 million (5%) due to higher revenues at existing businesses, $38 million due to the favorable effects of currency translation and $3 million due to an acquisition. The increase in revenue at existing businesses was due to higher demand with particular strength in sales of products sold through the segment’s healthcare market channel and, to a lesser extent, clinical diagnostic products.

Operating income margin was 25.6% in the first quarter of 2018 and 26.9% in the first quarter of 2017. The decrease resulted primarily from unfavorable sales mix and strategic growth investments, offset in part by profit on higher sales in local currencies and favorable foreign currency exchange.

Laboratory Products and Services

	Three Months Ended
	March 31,			April 1,
(Dollars in millions)	2018			2017			Change
Revenues	$	2,413		$	1,699		42	%
Operating Income Margin	11.6		%	12.7		%	-1.1 pt

Sales in the Laboratory Products and Services segment increased$714 million to $2.41 billion in the first quarter of 2018. Sales increased$554 million due to an acquisition, $98 million (6%) due to higher revenues at existing businesses and $62 million due to the favorable effects of currency translation. The increase in revenue at existing businesses was primarily due to increased demand for products sold through the segment's channel business and, to a lesser extent, its clinical trials business.

35

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

Operating income margin was 11.6% in the first quarter of 2018 and 12.7% in the first quarter of 2017. The decrease was primarily due to unfavorable sales mix and, to a lesser extent, strategic investments offset in part by profit on higher sales in local currencies.

Other Expense, Net

The company reported other expense, net, of $152 million and $117 million in the first quarter of 2018 and 2017, respectively (Note 5). Interest expense increased$28 million, primarily due to an increase in outstanding debt.

Provision for Income Taxes

The company recorded a $55 million provision for income taxes in the first quarter of 2018. In the first quarter of 2018, the company recorded a net tax provision of $21 million to adjust the estimated initial impacts of U.S. tax reform recorded in 2017, consisting of an incremental provision of $70 million offset in part by a $49 million reduction of related unrecognized tax benefits established in 2017. The adjustment was required based on new U.S. Treasury guidance released in the first quarter of 2018. The company expects its effective tax rate for all of 2018 will be between 6% and 9% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting purposes and are expected to total $525 to $575 million in 2018.

The company recorded a $48 million benefit from income taxes in the first quarter of 2017 as a result of a $65 million favorable adjustment to deferred tax balances due to extension of a tax holiday agreement in Singapore. The effective rate in both periods was also affected by relatively significant earnings in lower tax jurisdictions.

The company has operations and a taxable presence in approximately 50 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income, aside from any resulting one-time adjustment to the company’s deferred tax balances to reflect a new rate.

Recent Accounting Pronouncements

A description of recently issued accounting standards is included under the heading "Recent Accounting Pronouncements" in Note 1.

Contingent Liabilities

The company is contingently liable with respect to certain legal proceedings and related matters. An unfavorable outcome that differs materially from current accrual estimates, if any, for one or more of the matters described under the headings "Product Liability, Workers Compensation and Other Personal Injury Matters,""Intellectual Property Matters" and "Commercial Matters" in Note 9 could have a material adverse effect on the company’s financial position as well as its results of operations and cash flows.

Liquidity and Capital Resources

Consolidated working capital was $2.52 billion at March 31, 2018, compared with $2.37 billion at December 31, 2017. Included in working capital were cash and cash equivalents of $950 million at March 31, 2018 and $1.34 billion at December 31, 2017.

First Three Months of 2018

Cash provided by operating activities was $78 million during the first three months of 2018. Cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of $71 million and $124 million, respectively, primarily to support growth in sales in local currencies. An increase in other assets used cash of $192 million primarily due to the timing of income tax refunds and customer billings. Other liabilities decreased by $520 million primarily due to the timing of payments for incentive compensation and income taxes. Cash payments for income taxes increased to $331 million during the first three months of 2018, compared with $215 million in the first three months of 2017. The company made cash contributions to its pension and postretirement benefit plans totaling $24 million during the first three months of 2018. Payments for restructuring actions, principally severance costs and lease and other expenses of real estate consolidation, used cash of $23 million during the first three months of 2018.

36

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Liquidity and Capital Resources (continued)

During the first three months of 2018, the company’s investing activities used $179 million of cash. Acquisitions used cash of $57 million. The company’s investing activities also included the purchase of $118 million of property, plant and equipment.

The company’s financing activities used$342 million of cash during the first three months of 2018. Repayment of senior notes used cash of $453 million. A net increase in commercial paper obligations provided cash of $182 million. The company’s financing activities also included the payment of $60 million in cash dividends, offset in part by $39 million of net proceeds from employee stock option exercises. On July 7, 2016, the Board of Directors authorized the repurchase of up to $1.50 billion of the company’s common stock. At May 4, 2018, $500 million was available for future repurchases of the company’s common stock under this authorization. In May 2018, the company issued additional commercial paper obligations and used the proceeds and cash on hand to repay all of the $900 million principal balance of the 2.40% Senior Notes due 2019.

The company's commitments for purchases of property, plant and equipment, contractual obligations and other commercial commitments did not change materially between December 31, 2017 and March 31, 2018, except for changes in debt (discussed above). The company expects that for all of 2018, expenditures for property, plant and equipment, net of disposals, will approximate $700 to $730 million.

As of March 31, 2018, the company’s short-term debt totaled $2.81 billion including $1.17 billion of commercial paper obligations and $1.64 billion of senior notes due within the next twelve months. The company has a revolving credit facility with a bank group that provides up to $2.50 billion of unsecured multi-currency revolving credit. If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of March 31, 2018, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by approximately $75 million as a result of outstanding letters of credit.

Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S. including acquisitions and repayment of acquisition-related intercompany debt to the U.S. In addition, the company also transfers cash to the U.S. using non-taxable returns of capital as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.

The company believes that its existing cash and cash equivalents of $950 million as of March 31, 2018 and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.

First Three Months of 2017

Cash provided by operating activities was $361 million during the first three months of 2017. An increase in inventories used cash of $105 million primarily to support growth in sales in local currencies. An increase in other assets used cash of $134 million primarily due to the timing of payments. Other liabilities decreased by $303 million primarily due to the timing of payments for income taxes and incentive compensation. Cash payments for income taxes totaled $215 million. The company made cash contributions to its pension and postretirement benefit plans totaling $173 million during the first three months of 2017. Payments for restructuring actions, principally severance costs and lease and other expenses of real estate consolidation, used cash of $32 million during the first three months of 2017.

During the first three months of 2017, the company’s investing activities used $382 million of cash. Acquisitions used cash of $301 million. The company’s investing activities also included the purchase of $93 million of property, plant and equipment.

The company’s financing activities used$119 million of cash during the first three months of 2017. Issuance of debt provided cash of $519 million and an increase in commercial paper obligations provided cash of $566 million. Repayment of debt used cash of $703 million. The company’s financing activities also included the repurchase of $500 million of the company's common stock and the payment of $59 million in cash dividends, offset in part by $58 million of net proceeds from employee stock option exercises.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The company's exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure at year-end 2017.

37

THERMO FISHER SCIENTIFIC INC.

Item 4. Controls and Procedures

Management’s Evaluation of Disclosure Controls and Procedures

The company’s management, with the participation of the company’s chief executive officer and chief financial officer, evaluated the effectiveness of the company’s disclosure controls and procedures as of March 31, 2018. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of the company’s disclosure controls and procedures as of March 31, 2018, the company’s chief executive officer and chief financial officer concluded that, as of such date, the company’s disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended March 31, 2018, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See "Note 9 to our Consolidated Financial Statements – Commitments and Contingencies."

Item 1A. Risk Factors

Set forth below are the risks that we believe are material to our investors. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements beginning on page 30.

We must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to remain competitive. Our growth strategy includes significant investment in and expenditures for product development. We sell our products in several industries that are characterized by rapid and significant technological changes, frequent new product and service introductions and enhancements and evolving industry standards. Competitive factors include technological innovation, price, service and delivery, breadth of product line, customer support, e-business capabilities and the ability to meet the special requirements of customers. Our competitors may adapt more quickly to new technologies and changes in customers’ requirements than we can. Without the timely introduction of new products, services and enhancements, our products and services will likely become technologically obsolete over time, in which case our revenue and operating results would suffer.

Many of our existing products and those under development are technologically innovative and require significant planning, design, development and testing at the technological, product and manufacturing-process levels. Our customers use many of our products to develop, test and manufacture their own products. As a result, we must anticipate industry trends and develop products in advance of the commercialization of our customers’ products. If we fail to adequately predict our customers’ needs and future activities, we may invest heavily in research and development of products and services that do not lead to significant revenue.

38

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

It may be difficult for us to implement our strategies for improving internal growth. Some of the markets in which we compete have been flat or declining over the past several years. To address this issue, we are pursuing a number of strategies to improve our internal growth, including:

• strengthening our presence in selected geographic markets;

• allocating research and development funding to products with higher growth prospects;

• developing new applications for our technologies;

• expanding our service offerings;

• continuing key customer initiatives;

• combining sales and marketing operations in appropriate markets to compete more effectively;

• finding new markets for our products; and

• continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take advantage of our depth in product offerings.

We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.

Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate. Our business is affected by general economic conditions, both inside and outside the U.S. If the global economy and financial markets, or economic conditions in Europe, the U.S. or other key markets, are unstable, it could adversely affect the business, results of operations and financial condition of the company and its customers, distributors, and suppliers, having the effect of

• reducing demand for some of our products;

• increasing the rate of order cancellations or delays;

• increasing the risk of excess and obsolete inventories;

• increasing pressure on the prices for our products and services; and

• creating longer sales cycles and greater difficulty in collecting sales proceeds.

Demand for some of our products depends on capital spending policies of our customers and on government funding policies. Our customers include pharmaceutical and chemical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many factors, including public policy spending priorities, available resources and product and economic cycles, have a significant effect on the capital spending policies of these entities.

Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. An impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending.

As a multinational corporation, we are exposed to fluctuations in currency exchange rates, which could adversely affect our cash flows and results of operations. International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (the "functional currency"). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In the first three months of 2018, currency translation had a favorable effect of $209 million on revenues due to the weakening of the U.S. dollar relative to other currencies in which the company sells products and services.

Significant developments stemming from the U.S. administration or the U.K.’s referendum on membership in the EU could have an adverse effect on us. The U.S. administration has called for substantial changes to trade agreements, such as the North American Free Trade Agreement (NAFTA), and is imposing significant increases on tariffs on goods imported into the United States, particularly from China and Mexico. The administration has also indicated an intention to request Congress

39

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

to make significant changes, replacement or elimination of the Patient Protection and Affordable Care Act, and government negotiation/regulation of drug prices paid by government programs. Changes in U.S. social, political, regulatory and economic conditions or laws and policies governing the health care system and drug prices, foreign trade, manufacturing, and development and investment in the territories and countries where we or our customers operate could adversely affect our operating results and our business.

Additionally, on June 23, 2016, the United Kingdom held a referendum and voted in favor of leaving the European Union, or EU. This referendum has created political and economic uncertainty, particularly in the United Kingdom and the EU, and this uncertainty may last for years. Our business could be affected during this period of uncertainty, and perhaps longer, by the impact of the United Kingdom’s referendum. In addition, our business could be negatively affected by new trade agreements between the United Kingdom and other countries, including the United States, and by the possible imposition of trade or other regulatory barriers in the United Kingdom. These possible negative impacts, and others resulting from the United Kingdom’s actual or threatened withdrawal from the EU, may adversely affect our operating results and our customers’ businesses.

Our inability to protect our intellectual property could have a material adverse effect on our business. In addition, third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result. We place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with bringing new products through the development process and into the marketplace. Our success depends in part on our ability to develop patentable products and obtain and enforce patent protection for our products both in the United States and in other countries. We own numerous U.S. and foreign patents, and we intend to file additional applications, as appropriate, for patents covering our products. Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology. Any issued patents owned by or licensed to us may be challenged, invalidated or circumvented, and the rights under these patents may not provide us with competitive advantages. In addition, competitors may design around our technology or develop competing technologies. Intellectual property rights may also be unavailable or limited in some foreign countries, which could make it easier for competitors to capture increased market position. We could incur substantial costs to defend ourselves in suits brought against us or in suits in which we may assert our patent rights against others. An unfavorable outcome of any such litigation could materially adversely affect our business and results of operations.

We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with our collaborators, employees and consultants. These agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently developed by our competitors.

Third parties may assert claims against us to the effect that we are infringing on their intellectual property rights. Our Life Technologies subsidiary is party to certain lawsuits in which plaintiffs claim we infringe their intellectual property (Note 9). We could incur substantial costs and diversion of management resources in defending these claims, which could have a material adverse effect on our business, financial condition and results of operations. In addition, parties making these claims could secure a judgment awarding substantial damages, as well as injunctive or other equitable relief, which could effectively block our ability to make, use, sell, distribute, or market our products and services in the United States or abroad. In the event that a claim relating to intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.

Changes in governmental regulations may reduce demand for our products or increase our expenses. We compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations could reduce demand for our products or increase our expenses. For example, many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs. Changes in the U.S. Food and Drug Administration’s regulation of the drug discovery and development process could have an adverse effect on the demand for these products.

Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could suffer. Our pharma services offerings are highly exacting and complex, due in part to strict quality and regulatory requirements. Our operating results in this business depend on our ability to execute and, when

40

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

necessary, improve our quality management strategy and systems, and our ability to effectively train and maintain our employee base with respect to quality management. A failure of our quality control systems could result in problems with facility operations or preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations. Such problems could affect production of a particular batch or series of batches of products, requiring the destruction of such products or a halt of facility production altogether.

In addition, our failure to meet required quality standards may result in our failure to timely deliver products to our customers, which in turn could damage our reputation for quality and service. Any such failure could, among other things, lead to increased costs, lost revenue, reimbursement to customers for lost drug product, registered intermediates, registered starting materials, and active pharmaceutical ingredients, other customer claims, damage to and possibly termination of existing customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. Production problems in our drug and biologic manufacturing operations could be particularly significant because the cost of raw materials for such manufacturing is often high. If problems in preparation or manufacture of a product or failures to meet required quality standards for that product are not discovered before such product is released to the market, we may be subject to adverse regulatory actions, including product recalls, product seizures, injunctions to halt manufacture and distribution, restrictions on our operations, civil sanctions, including monetary sanctions, and criminal actions. In addition, such problems or failures could subject us to litigation claims, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant.

We are subject to product and other liability risks for which we may not have adequate insurance coverage. We may be named as a defendant in product liability lawsuits, which may allege that products or services we have provided from our pharma services offerings have resulted or could result in an unsafe condition or injury to consumers. Additionally, products currently or previously sold by our environmental and process instruments and radiation measurement and security instruments businesses include fixed and portable instruments used for chemical, radiation and trace explosives detection. These products are used in airports, embassies, cargo facilities, border crossings and other high-threat facilities for the detection and prevention of terrorist acts. If any of these products were to malfunction, it is possible that explosive or radioactive material could fail to be detected by our product, which could lead to product liability claims. There are also many other factors beyond our control that could lead to liability claims, such as the reliability and competence of the customers’ operators and the training of such operators.

Any such product liability claims brought against us could be significant and any adverse determination may result in liabilities in excess of our insurance coverage. Although we carry product liability insurance, we cannot be certain that our current insurance will be sufficient to cover these claims or that it can be maintained on acceptable terms, if at all.

Our inability to complete any pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect on our business. Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services. Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals. Any acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company. Further, we may not be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated cost savings or synergies, if any, from these acquisitions, which could adversely affect our business.

Moreover, we have acquired many companies and businesses. As a result of these acquisitions, we recorded significant goodwill and indefinite-lived intangible assets (primarily tradenames) on our balance sheet, which amount to approximately $25.36 billion and $1.29 billion, respectively, as of March 31, 2018. In addition, we have definite-lived intangible assets totaling $15.11 billion as of March 31, 2018. We assess the realizability of goodwill and indefinite-lived intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We assess the realizability of definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances would generally include operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the goodwill and intangible assets will depend on the future cash flows of these businesses. These cash flows in turn depend in part on how well we have integrated these businesses. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets.

We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenue associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. The laws

41

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

Because we compete directly with certain of our larger customers and product suppliers, our results of operations could be adversely affected in the short term if these customers or suppliers abruptly discontinue or significantly modify their relationship with us. Our largest customer in the laboratory products business is also a significant competitor. Our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customers results in a discontinuation of their purchases from us. In addition, we manufacture products that compete directly with products that we source from third-party suppliers. We also source competitive products from multiple suppliers. Our business could be adversely affected in the short term if any of our large third-party suppliers abruptly discontinues selling products to us.

Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability. We ship a significant portion of our products to our customers through independent package delivery companies, such as Federal Express in the U.S. and DHL in Europe. We also maintain a small fleet of vehicles dedicated to the delivery of our products and ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal Service. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.

We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies. We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the U.S. Federal Drug Administration (the FDA), the U.S. Drug Enforcement Agency (the DEA), various state boards of pharmacy, state health departments, the U.S. Department of Health and Human Services (the DHHS), the European Medicines Agency (the EMA), in Europe, the EU member states and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices and drug safety. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of the DEA, the FDA, the DHHS, foreign agencies including the EMA, and other various state boards of pharmacy, state health departments and/or comparable state agencies as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale.

The manufacture, distribution and marketing of many of our products and services, including medical devices and pharma services, are subject to extensive ongoing regulation by the FDA, the DEA, the EMA, and other equivalent local, state, federal and non-U.S. regulatory authorities. In addition, we are subject to inspections by these regulatory authorities. Failure by us or by our customers to comply with the requirements of these regulatory authorities, including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number of pharmaceuticals for many of our customers and a negative regulatory event could impact our customers' ability to provide products to their customers.

We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the importation and exportation of products, the handling, transportation and manufacture of substances that could be classified as hazardous, and our business practices in the U.S. and abroad such as anti-corruption, anti-competition and privacy and data protection laws. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations.

Our business could be adversely affected by disruptions at our sites. We rely upon our manufacturing operations to produce many of the products we sell and our warehouse facilities to store products, pending sale. Any significant disruption of

42

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

those operations for any reason, such as strikes or other labor unrest, power interruptions, fire, hurricanes or other events beyond our control could adversely affect our sales and customer relationships and therefore adversely affect our business. We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. Although most of our raw materials are available from a number of potential suppliers, our operations also depend upon our ability to obtain raw materials at reasonable prices. If we are unable to obtain the materials we need at a reasonable price, we may not be able to produce certain of our products or we may not be able to produce certain of these products at a marketable price, which could have an adverse effect on our results of operations.

Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows. As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.

We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flow. Our primary commodity exposures are for fuel, petroleum-based resins and steel. While we may seek to minimize the impact of price increases through higher prices to customers and various cost-saving measures, our earnings and cash flows could be adversely affected in the event these measures are insufficient to cover our costs.

A significant disruption in, or breach in security of, our information technology systems could adversely affect our business. As a part of our ongoing effort to upgrade our current information systems, we periodically implement new enterprise resource planning software and other software applications to manage certain of our business operations. As we implement and add functionality, problems could arise that we have not foreseen. Such problems could disrupt our ability to provide quotes, take customer orders and otherwise run our business in a timely manner. When we upgrade or change systems, we may suffer interruptions in service, loss of data or reduced functionality. In addition, if our new systems fail to provide accurate pricing and cost data our results of operations and cash flows could be adversely affected.

We also rely on our technology infrastructure, among other functions, to interact with suppliers, sell our products and services, fulfill orders and bill, collect and make payments, ship products, provide services and support to customers, track customers, fulfill contractual obligations and otherwise conduct business. Our systems may be vulnerable to damage or interruption from natural disasters, power loss, telecommunication failures, terrorist attacks, computer viruses, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, interruptions in our services, which could harm our reputation and financial results. Any of the cyber-attacks, breaches or other disruptions or damage described above, if significant, could materially interrupt our operations, delay production and shipments, result in theft of our and our customers’ intellectual property and trade secrets, damage customer, business partner and employee relationships and our reputation or result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased cost for security and remediation, each of which could adversely affect our business and financial results.

Our debt may restrict our investment opportunities or limit our activities. As of March 31, 2018, we had approximately $20.94 billion in outstanding indebtedness. In addition, we have availability to borrow under a revolving credit facility that provides for up to $2.50 billion of unsecured multi-currency revolving credit. We may also obtain additional long-term debt and lines of credit to meet future financing needs, which would have the effect of increasing our total leverage.

Our leverage could have negative consequences, including increasing our vulnerability to adverse economic and industry conditions, limiting our ability to obtain additional financing and limiting our ability to acquire new products and technologies through strategic acquisitions.

Our ability to make scheduled payments, refinance our obligations or obtain additional financing will depend on our future operating performance and on economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our obligations. If we are unable to service our debt, refinance our existing debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or research and development expenditures.

Additionally, the agreements governing our debt require that we maintain certain financial ratios, and contain affirmative and negative covenants that restrict our activities by, among other limitations, limiting our ability to incur additional

43

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

indebtedness, merge or consolidate with other entities, make investments, create liens, sell assets and enter into transactions with affiliates. The covenants in our revolving credit facility (the Facility) include a Consolidated Leverage Ratio (total debt-to-Consolidated EBITDA) and a Consolidated Interest Coverage Ratio (Consolidated EBITDA to Consolidated Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a maximum Consolidated Leverage Ratio of 4.0:1.0 through the second quarter of 2018 and then stepping down to 3.5:1.0 for the third quarter of 2018 and thereafter. The company has also agreed that so long as any lender has any commitment under the Facility or any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.0:1.0 as of the last day of any fiscal quarter.

Our ability to comply with these financial restrictions and covenants is dependent on our future performance, which is subject to prevailing economic conditions and other factors, including factors that are beyond our control such as foreign exchange rates and interest rates. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under that instrument and require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under certain of our debt instruments would trigger an event of default under other of our debt instruments.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

There was no share repurchase activity for the company's first quarter of 2018. On July 7, 2016, the Board of Directors authorized the repurchase of up to $1.50 billion of the company’s common stock. At March 31, 2018, $500 million was available for future repurchases of the company’s common stock under this authorization.

Item 6. Exhibits

See Exhibit Index on page 46.

44

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:	May 4, 2018	THERMO FISHER SCIENTIFIC INC.
		/s/ Stephen Williamson
		Stephen Williamson
		Senior Vice President and Chief Financial Officer
		/s/ Peter E. Hornstra
		Peter E. Hornstra
		Vice President and Chief Accounting Officer

45

THERMO FISHER SCIENTIFIC INC.

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
10.1	Summary of 2018 Annual Cash Incentive Plan Matters (set forth in Item 5.02 to the Registrant’s Current Report on Form 8-K filed March 1, 2018 [File No.1-8002] under the heading "Compensatory Arrangements of Certain Officers" and incorporated in this document by reference).*
10.2	Form of Executive Change in Control Retention Agreement for Officers (other than Marc Casper).*
10.3	Amendment No. 2 to Executive Change in Control Retention Agreement, dated March 16, 2018, between Marc N. Casper and the Registrant.*
31.1	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Definition Linkbase Document.
101.LAB	XBRL Taxonomy Label Linkbase Document.
101.PRE	XBRL Taxonomy Presentation Linkbase Document.
	The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries.

 _______________________

*Indicates management contract or compensatory plan, contract or arrangement.

** Certification is not deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheet at March 31, 2018 and December 31, 2017, (ii) Consolidated Statement of Income for the three months endedMarch 31, 2018 and April 1, 2017, (iii) Consolidated Statement of Comprehensive Income for the three months endedMarch 31, 2018 and April 1, 2017, (iv) Consolidated Statement of Cash Flows for the three months ended March 31, 2018 and April 1, 2017, (v) Consolidated Statement of Shareholders’ Equity for the three months ended March 31, 2018 and April 1, 2017 and (vi) Notes to Consolidated Financial Statements.

46

EX-10.2

2/27/18 Officer Form Page 1 of 13

Exhibit 10.2

EXECUTIVE CHANGE IN CONTROL RETENTION AGREEMENT

THIS AGREEMENT by and between THERMO FISHER SCIENTIFIC INC., a Delaware corporation (the “Company”), and _____________________ (the “Executive”) is made as of _______, 2018 (the “Effective Date”).

WHEREAS, the Company recognizes that, as is the case with many publicly‑held corporations, the possibility of a change in control of the Company exists and that such possibility, and the uncertainty and questions which it may raise among key personnel, may result in the departure or distraction of key personnel to the detriment of the Company and its stockholders; and

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that appropriate steps should be taken to reinforce and encourage the continued employment and dedication of the Company's key personnel without distraction from the possibility of a change in control of the Company and related events and circumstances;

NOW, THEREFORE, as an inducement for and in consideration of the Executive remaining in its employ, the Company agrees that the Executive shall receive the severance benefits set forth in this Agreement in the event the Executive's employment with the Company is terminated under the circumstances described below subsequent to a Change in Control Date (as defined in Section 1.2).

1.    Key Definitions.

As used herein, the following terms shall have the following respective meanings:

1.1    “Change in Control” means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a)    the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d‑3 promulgated under the Exchange Act) 50% or more of either (i) the then‑outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then‑outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by the Company, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (iii) any acquisition

2/27/18 Officer Form Page 2 of 13

by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this Section 1.1; or

(b)    such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term “Continuing Director” means at any date a member of the Board (i) who was a member of the Board on the date of the execution of this Agreement or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or

(c)    the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a “Business Combination”), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then‑outstanding shares of common stock and the combined voting power of the then‑outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the “Acquiring Corporation”) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; and (ii) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 50% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then‑outstanding securities of such corporation entitled to vote generally in the election of directors.

1.2     “Change in Control Date” means the first date during the Term (as defined in Section 2) on which a Change in Control occurs. Anything in this Agreement to the contrary notwithstanding, if (a) a Change in Control occurs, (b) the Executive's employment with the Company is terminated prior to the date on which the Change in Control occurs, and (c) it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a third party who has taken steps reasonably calculated to effect a Change in Control or (ii) otherwise arose in connection with or in anticipation of a Change in Control, then for all purposes of this Agreement the “Change in Control Date” shall mean the date immediately prior to the date of such termination of employment.

2/27/18 Officer Form Page 3 of 13

1.3    “Cause” means the Executive's willful engagement in illegal conduct or gross misconduct after the Change in Control Date which is materially and demonstrably injurious to the Company. For purposes of this Section 1.3, no act or failure to act by the Executive shall be considered “willful” unless it is done, or omitted to be done, in bad faith and without reasonable belief that the Executive's action or omission was in the best interests of the Company.

1.4    “Good Reason” means the occurrence, without the Executive's written consent, of any of the events or circumstances set forth in clauses (a) through (g) below. Notwithstanding the occurrence of any such event or circumstance, such occurrence shall not be deemed to constitute Good Reason if, prior to the Date of Termination specified in the Notice of Termination (each as defined in Section 3.2(a)) given by the Executive in respect thereof, such event or circumstance has been fully corrected and the Executive has been reasonably compensated for any losses or damages resulting therefrom (provided that such right of correction by the Company shall only apply to the first Notice of Termination for Good Reason given by the Executive).

(a)    the assignment to the Executive of duties inconsistent in any material respect with the Executive's position (including status, offices, titles and reporting requirements), authority or responsibilities in effect immediately prior to the earliest to occur of (i) the Change in Control Date, (ii) the date of the execution by the Company of the initial written agreement or instrument providing for the Change in Control or (iii) the date of the adoption by the Board of Directors of a resolution providing for the Change in Control (with the earliest to occur of such dates referred to herein as the “Measurement Date”) or a material diminution in such position, authority or responsibilities;

(b)    a reduction in the Executive's annual base salary as in effect on the Measurement Date or as the same was or may be increased thereafter from time to time;

(c)    the failure by the Company to (i) continue in effect any material compensation or benefit plan or program, including without limitation any life insurance, medical, health and accident or disability plan and any vacation or automobile program or policy, in which the Executive participates or which is applicable to the Executive immediately prior to the Measurement Date (a “Benefit Plan”), unless an equitable arrangement (embodied in an ongoing substitute or alternative plan) has been made with respect to such plan or program, (ii) continue the Executive's participation therein (or in such substitute or alternative plan) on a basis not materially less favorable than the basis existing immediately prior to the Measurement Date (iii) award cash bonuses to the Executive in amounts and in a manner substantially consistent with past practice in light of the Company's financial performance or (iv) continue to provide any material fringe benefit enjoyed by Executive immediately prior to the Measurement Date;

(d)    a change by the Company in the location at which the Executive performs the Executive’s principal duties for the Company to a new location that is both (i) outside a radius of 50 miles from the Executive's principal residence immediately prior to the Measurement Date and (ii) more than 30 miles from the location at which the Executive performed the Executive’s principal duties for the Company immediately prior to the Measurement Date; or a requirement by

2/27/18 Officer Form Page 4 of 13

the Company that the Executive travel on Company business to a substantially greater extent than required immediately prior to the Measurement Date;

(e)    the failure of the Company to obtain the agreement from any successor to the Company to assume and agree to perform this Agreement, as required by Section 6.1;

(f)    a purported termination of the Executive's employment which is not effected pursuant to a Notice of Termination satisfying the requirements of Section 3.2(a); or

(g)    any failure of the Company to pay or provide to the Executive any portion of the Executive's compensation or benefits due under any Benefit Plan within seven days of the date such compensation or benefits are due, or any material breach by the Company of this Agreement or any employment agreement with the Executive.

The Executive's right to terminate the Executive’s employment for Good Reason shall not be affected by the Executive’s incapacity due to physical or mental illness.

1.5    “Disability” means the Executive's inability, due to a physical or mental disability, for a period of 90 days, whether or not consecutive, during any 360-day period to perform the Executive’s duties on behalf of the Company, with or without reasonable accommodation as that term is defined under state or federal law. A determination of disability shall be made by a physician satisfactory to both the Executive and the Company, providedthat if the Executive and the Company do not agree on a physician, the Executive and the Company shall each select a physician and these two together shall select a third physician, whose determination as to disability shall be binding on all parties.

    2.    Term of Agreement. This Agreement, and all rights and obligations of the parties hereunder, shall take effect upon the Effective Date and shall expire upon the first to occur of (a) the expiration of the Term (as defined below) if a Change in Control has not occurred during the Term, (b) the date 18 months after the Change in Control Date, if the Executive is still employed by the Company as of such later date, or (c) the fulfillment by the Company of all of its obligations under Sections 4 and 5.2 if the Executive's employment with the Company terminates within 18 months following the Change in Control Date. “Term” shall mean the period commencing as of the Effective Date and continuing in effect through May 15, 2023.

3.    Employment Status; Termination Following Change in Control.

3.1    Not an Employment Contract. The Executive acknowledges that this Agreement does not constitute a contract of employment or impose on the Company any obligation to retain the Executive as an employee and that this Agreement does not prevent the Executive from terminating employment at any time. If the Executive's employment with the Company terminates for any reason and subsequently a Change in Control shall occur, the Executive shall not be entitled to any benefits hereunder except as otherwise provided pursuant to Section 1.2.

2/27/18 Officer Form Page 5 of 13

3.2    Termination of Employment.     

(a)    If the Change in Control Date occurs during the Term, any termination of the Executive's employment by the Company or by the Executive within 18 months following the Change in Control Date (other than due to the death of the Executive) shall be communicated by a written notice to the other party hereto (the “Notice of Termination”), given in accordance with Section 7. Any Notice of Termination shall: (i) indicate the specific termination provision (if any) of this Agreement relied upon by the party giving such notice, (ii) to the extent applicable, set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive's employment under the provision so indicated and (iii) specify the Date of Termination (as defined below). The effective date of an employment termination (the “Date of Termination”) shall be the close of business on the date specified in the Notice of Termination (which date may not be less than 15 days or more than 120 days after the date of delivery of such Notice of Termination), in the case of a termination other than one due to the Executive's death, or the date of the Executive's death, as the case may be. In the event the Company fails to satisfy the requirements of Section 3.2(a) regarding a Notice of Termination, the purported termination of the Executive’s employment pursuant to such Notice of Termination shall not be effective for purposes of this Agreement.    

(b)    The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting any such fact or circumstance in enforcing the Executive's or the Company's rights hereunder.

(c)    Any Notice of Termination for Cause given by the Company must be given within 90 days of the occurrence of the event(s) or circumstance(s) which constitute(s) Cause. Prior to any Notice of Termination for Cause being given (and prior to any termination for Cause being effective), the Executive shall be entitled to a hearing before the Board at which the Executive may, at the Executive’s election, be represented by counsel and at which the Executive shall have a reasonable opportunity to be heard. Such hearing shall be held on not less than 15 days prior written notice to the Executive stating the Board’s intention to terminate the Executive for Cause and stating in detail the particular event(s) or circumstance(s) which the Board believes constitutes Cause for termination.

(d)    Any Notice of Termination for Good Reason given by the Executive must be given within 90 days of the occurrence of the event(s) or circumstance(s) which constitute(s) Good Reason.

2/27/18 Officer Form Page 6 of 13

4.    Benefits to Executive.

4.1    Compensation. If the Change in Control Date occurs during the Term and the Executive's employment with the Company terminates within 18 months following the Change in Control Date, the Executive shall be entitled to the following benefits:

(a)    Termination Without Cause or for Good Reason. If the Executive's employment with the Company is terminated by the Company (other than for Cause, Disability or death) or by the Executive for Good Reason within 18 months following the Change in Control Date, then the Executive shall be entitled to the following benefits:        

(i)    the Company shall pay to the Executive in a lump sum in cash within 30 days after the Date of Termination the aggregate of the following amounts:

(1)    the sum of (A) the Executive's base salary through the Date of Termination, (B) the product of (x) the higher of the Executive’s target bonus as in effect immediately prior to the Measurement Date or the Termination Date and (y) a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination, and the denominator of which is 365 and (C) the amount of any accrued vacation pay, to the extent not previously paid (the sum of the amounts described in clauses (A), (B), and (C) shall be hereinafter referred to as the “Accrued Obligations”); and

(2)    an amount equal to (a) two and one half (2.5) multiplied by (b) the sum of (x) the higher of the Executive’s annual base salary as in effect immediately prior to the Measurement Date or the Termination Date and (y) the higher of the Executive’s target bonus as in effect immediately prior to the Measurement Date or the Termination Date.

(ii)    for two years after the Date of Termination, or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, the Company shall continue to provide medical, dental and life insurance benefits to the Executive and the Executive's family at least equal to those which would have been provided to them if the Executive's employment had not been terminated, in accordance with the applicable medical, dental and life insurance Benefit Plans in effect on the Measurement Date or, if more favorable to the Executive and the Executive’s family, in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies; provided, however, that (A) if the terms of a medical, dental or life insurance Benefit Plan do not permit continued participation therein by a former employee, then an equitable arrangement shall be made by the Company (such as a substitute or alternative plan) to provide as substantially equivalent a benefit as is reasonably possible and (B) if the Executive becomes reemployed with another employer and is eligible to receive a particular type of benefits (e.g., medical insurance benefits) from such employer on terms at least as favorable to the Executive and the Executive’s family as those being provided by the Company, then the Company shall no longer be required to provide those particular benefits to the Executive and the Executive’s family; and

2/27/18 Officer Form Page 7 of 13

(iii)    to the extent not previously paid or provided, the Company shall timely pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive following the Executive's termination of employment under any plan, program, policy, practice, contract or agreement of the Company and its affiliated companies (other than severance benefits) (such other amounts and benefits shall be hereinafter referred to as the “Other Benefits”).

(b)    Resignation without Good Reason; Termination for Death or Disability. If the Executive voluntarily terminates the Executive’s employment with the Company within 18 months following the Change in Control Date, excluding a termination for Good Reason, or if the Executive's employment with the Company is terminated by reason of the Executive's death or Disability within 18 months following the Change in Control Date, then the Company shall (i) pay the Executive (or the Executive’s estate, if applicable), in a lump sum in cash within 30 days after the Date of Termination, the Accrued Obligations and (ii) timely pay or provide to the Executive the Other Benefits.

(c)    Termination for Cause. If the Company terminates the Executive's employment with the Company for Cause within 18 months following the Change in Control Date, then the Company shall (i) pay the Executive, in a lump sum in cash within 30 days after the Date of Termination, the Executive's annual base salary through the Date of Termination, and (ii) timely pay or provide to the Executive the Other Benefits.

4.2    Taxes.

(a)    Notwithstanding any other provision of this Agreement, except as set forth in Section 4.2(b), in the event that the Company undergoes a “Change in Ownership or Control” (as defined below), the Company shall not be obligated to provide to the Executive a portion of any “Contingent Compensation Payments” (as defined below) that the Executive would otherwise be entitled to receive to the extent necessary to eliminate any “excess parachute payments” (as defined in Section 280G(b)(1) of the Internal Revenue Code of 1986, as amended (the “Code”)) for the Executive. For purposes of this Section 4.2, the Contingent Compensation Payments so eliminated shall be referred to as the “Eliminated Payments” and the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated shall be referred to as the “Eliminated Amount.”

(b)    Notwithstanding the provisions of Section 4.2(a), no such reduction in Contingent Compensation Payments shall be made if (i) the Eliminated Amount (computed without regard to this sentence) exceeds (ii) 110% of the aggregate present value (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional taxes that would be incurred by the Executive if the Eliminated Payments (determined without regard to this sentence) were paid to the Executive (including, state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in excess of the Executive’s “base amount” (as defined in Section

2/27/18 Officer Form Page 8 of 13

280G(b)(3) of the Code), and any withholding taxes). The override of such reduction in Contingent Compensation Payments pursuant to this Section 4.2(b) shall be referred to as a Section 4.2(b) Override.” For purpose of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law.

(c)    For purposes of this Section 4.3 the following terms shall have the following respective meanings:

(i)    “Change in Ownership or Control” shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code.

(ii)    “Contingent Compensation Payment” shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement or otherwise) to a “disqualified individual” (as defined in Section 280G(c) of the Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.

(d)    Any payments or other benefits otherwise due to the Executive following a Change in Ownership or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the “Potential Payments”) shall not be made until the dates provided for in this Section 4.2(d). Within 30 days after each date on which the Executive first becomes entitled to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify the Executive (with reasonable detail regarding the basis for its determinations) (i) which Potential Payments constitute Contingent Compensation Payments, (ii) the Eliminated Amount and (iii) whether the Section 4.2(b) Override is applicable. Within 30 days after delivery of such notice to the Executive, the Executive shall deliver a response to the Company (the “Executive Response”) stating either (A) that the Executive agrees with the Company’s determination pursuant to the preceding sentence or (B) that the Executive disagrees with such determination, in which case the Executive shall set forth (i) which Potential Payments should be characterized as Contingent Compensation Payments, (ii) the Eliminated Amount, and (iii) whether the Section 4.2(b) Override is applicable. In the event that the Executive fails to deliver an Executive Response on or before the required date, the Company’s initial determination shall be final and the Contingent Compensation Payments that shall be treated as Eliminated Payments shall be determined by reducing or eliminating the amounts payable under this Agreement in the following order: (i) cash payments, (ii) taxable benefits, (iii) nontaxable benefits and (iv) accelerated vesting of equity awards. If the Executive states in the Executive Response that the Executive agrees with the Company’s determination, the Company shall make the Potential Payments to the Executive at the time set forth in Section 4.3(d) (except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due). If the Executive states in the Executive Response that the Executive disagrees with the Company’s determination, then, for a period of

2/27/18 Officer Form Page 9 of 13

15 days following delivery of the Executive Response, the Executive and the Company shall use good faith efforts to resolve such dispute. If such dispute is not resolved within such 15-day period, such dispute shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator’s award in any court having jurisdiction. The Company shall make to the Executive at the time set forth in Section 4.3(d)those Potential Payments as to which there is no dispute between the Company and the Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due). The balance of the Potential Payments shall be made within three business days following the resolution of such dispute. Subject to the limitations contained in Sections 4.2(a) and (b) hereof, the amount of any payments to be made to the Executive following the resolution of such dispute shall be increased by amount of the accrued interest thereon computed at the prime rate announced from time to time by The Wall Street Journal, compounded monthly from the date that such payments originally were due.

4.3    Payments Subject to Section 409A.

(a)    Subject to this Section 4.3, payments or benefits under Section 4.1 shall begin only upon the date of a “separation from service” of the Executive (determined as set forth below) which occurs on or after the termination of the Executive’s employment. The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to the Executive under Section 4.1, as applicable:

(i)    It is intended that each installment of the payments and benefits provided under Section 4.1 shall be treated as a separate “payment” for purposes of Section 409A of the Code and the guidance issued thereunder (“Section 409A”). Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.

(ii)    If, as of the date of the “separation from service” of the Executive from the Company, the Executive is not a “specified employee” (within the meaning of Section 409A), then each installment of the payments and benefits shall be made on the dates and terms set forth in Section 4.1.

(iii)    If, as of the date of the “separation from service” of the Executive from the Company, the Executive is a “specified employee” (within the meaning of Section 409A), then:

(1)    Each installment of the payments and benefits due under Section 4.1 that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the Short-Term Deferral Period (as hereinafter defined) shall be treated as a short-term deferral within the meaning of Treasury Regulation § 1.409A-1(b)(4) to the maximum extent permissible under Section 409A. For purposes of this Agreement, the “Short-Term Deferral Period” means the period ending

2/27/18 Officer Form Page 10 of 13

on the later of the 15^th day of the third month following the end of the Executive’s tax year in which the separation from service occurs and the 15^th day of the third month following the end of the Company’s tax year in which the separation from service occurs; and

(2)    Each installment of the payments and benefits due under Section 4.1 that is not described in Section 4.3(a)(iii)(1) and that would, absent this subsection, be paid within the six-month period following the “separation from service” of the Executive from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the Executive’s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following the Executive’s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation § 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation § 1.409A-1(b)(9)(iii) must be paid no later than the last day of the Executive’s second taxable year following his taxable year in which the separation from service occurs.

(b)    The determination of whether and when a separation from service of the Executive from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation § 1.409A-1(h). Solely for purposes of this Section 4.3(b), “Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.

(c)    All reimbursements and in-kind benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A.

(d)    The provisions of Section 4.6 shall be applied as follows: Payment of benefits under this Agreement shall be made on (or, with respect to in kind benefits subject to Section 409A, commence on) the 60^th day following the Employee’s separation from service, provided that the Employee has by that time executed and submitted the release of claims and separation agreement described in Section 4.6, and provided that the payments are not disputed under the procedures set forth in Section 4.2.

(e)    The terms of this Agreement shall be interpreted as necessary to provide payments that comply with (or are exempt from) the requirements of Section 409A.

4.4    Outplacement Services. In the event the Executive is terminated by the Company (other than for Cause, Disability or death), or the Executive terminates employment for Good Reason, within 18 months following the Change in Control Date, the Company shall provide outplacement services through one or more outside firms of the Executive’s choosing up to an aggregate of $20,000, with such services to extend until the earlier of (i) 12 months following the

2/27/18 Officer Form Page 11 of 13

termination of the Executive’s employment or (ii) the date the Executive secures full time employment.

4.5    Mitigation. The Executive shall not be required to mitigate the amount of any payment or benefits provided for in this Section 4 by seeking other employment or otherwise. Further, except as provided in Section 4.1(a)(ii), the amount of any payment or benefits provided for in this Section 4 shall not be reduced by any compensation earned by the Executive as a result of employment by another employer, by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company or otherwise.

4.6    Release of Claims by Executive. The Executive shall not be entitled to any payments or other benefits hereunder unless the Executive executes and, if applicable, does not revoke, a full and complete release and separation agreement in the form to be provided by the Company.

5.    Disputes.

5.1    Settlement of Disputes; Arbitration. All claims by the Executive for benefits under this Agreement shall be directed to and determined by the Board and shall be in writing. Any denial by the Board of Directors of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial. The Board shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim. Any further dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator's award in any court having jurisdiction.

5.2    Expenses. In the event of any arbitration, claim, demand or suit arising out of or with respect to this Agreement, including any action for injunctive relief and any contest regarding the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive regarding the amount of any payment or benefits pursuant to this Agreement), the prevailing party shall be entitled to reasonable costs and attorneys’ fees, including any such costs and fees upon appeal.

6.    Successors.

6.1    Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no such succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a breach of this Agreement and shall constitute Good Reason if the Executive elects to terminate employment, except that for purposes of implementing the foregoing, the date on which any such succession becomes effective shall be deemed the Date of Termination. As used in this Agreement, “Company” shall mean the Company as defined above

2/27/18 Officer Form Page 12 of 13

and any successor to its business or assets as aforesaid which assumes and agrees to perform this Agreement, by operation of law or otherwise.

6.2    Successor to Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive's personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive should die while any amount would still be payable to the Executive or the Executive’s family hereunder if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives or administrators of the Executive's estate.

7.    Notice. All notices, instructions and other communications given hereunder or in connection herewith shall be in writing. Any such notice, instruction or communication shall be sent either (i) by registered or certified mail, return receipt requested, postage prepaid, or (ii) prepaid via a reputable nationwide overnight courier service, in each case addressed to the Company, at 81 Wyman Street, Waltham, Massachusetts and to the Executive at the Executive’s principal residence as currently reflected on the Company’s records (or to such other address as either the Company or the Executive may have furnished to the other in writing in accordance herewith). Any such notice, instruction or communication shall be deemed to have been delivered five business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service. Either party may give any notice, instruction or other communication hereunder using any other means, but no such notice, instruction or other communication shall be deemed to have been duly delivered unless and until it actually is received by the party for whom it is intended.

8.    Miscellaneous.

8.1    Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

8.2    Injunctive Relief. The Company and the Executive agree that any breach of this Agreement by the Company is likely to cause the Executive substantial and irrevocable damage and therefore, in the event of any such breach, in addition to such other remedies which may be available, the Executive shall have the right to specific performance and injunctive relief.

8.3    Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the internal laws of the Commonwealth of Massachusetts, without regard to conflicts of law principles.

8.4    Waivers. No waiver by the Executive at any time of any breach of, or compliance with, any provision of this Agreement to be performed by the Company shall be deemed a waiver of that or any other provision at any subsequent time.

2/27/18 Officer Form Page 13 of 13

8.5    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original but both of which together shall constitute one and the same instrument.

8.6    Tax Withholding. Any payments provided for hereunder shall be paid net of any applicable tax withholding required under federal, state or local law.

8.7    Entire Agreement. This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein; and any prior agreement of the parties hereto in respect of the subject matter contained herein is hereby terminated and cancelled.

8.8    Amendments. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement under seal as of the day and year first set forth above.

THERMO FISHER SCIENTIFIC INC.

By:

EXECUTIVE

EX-10.3

Exhibit 10.3

THERMO FISHER SCIENTIFIC INC.

AMENDMENT NO. 2 TO

EXECUTIVE CHANGE IN CONTROL RETENTION AGREEMENT

This AMENDMENT NO. 2 (the “Amendment”) to the Executive Change in Control Retention Agreement dated November 21, 2009 (the “Agreement”) by and between Thermo Fisher Scientific Inc. (the “Company”) and Marc N. Casper (the “Executive”) is made as of March 16, 2018. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

WHEREAS, the Company and the Executive entered into the Agreement to provide separation pay and benefits to the Executive in the event the Executive’s employment with the Company is terminated under certain circumstances;

WHEREAS, the Agreement was amended by Amendment No. 1 to the Agreement dated November 30, 2010 to reflect compliance with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended; and

WHEREAS, the Company desires to further amend the Agreement.

NOW, THEREFORE, in consideration for the mutual promises contained herein, the parties hereby agree as follows.

1. Section 3.1(a)(i)(2) of the Agreement is hereby amended and restated in its entirety as follows:

“(2) an amount equal to (a) two and one half (2.5) multiplied by (b) the sum of (x) the higher of the Executive’s annual base salary as in effect immediately prior to the Change in Control Date or the Date of Termination and (y) the higher of the Executive’s target bonus as in effect immediately prior to the Change in Control Date or the Date of Termination.”

2. Except as expressly modified herein, the Agreement shall remain in full force and effect.

3. This Amendment may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall be one and the same document.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, this Amendment has been duly executed and delivered by the parties hereto as of the day and year first above written.

THERMO FISHER SCIENTIFIC INC.
By:	/s/ Michael A. Boxer
	Name: Michael A. Boxer
	Title: Senior Vice President and General Counsel
MARC N. CASPER
	/s/ Marc N. Casper

- 2 -

EX-31.1

Exhibit 31.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc N. Casper, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2018

/s/ Marc N. Casper

Marc N. Casper

President and Chief Executive Officer

EX-31.2

Exhibit 31.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen Williamson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2018

/s/ Stephen Williamson

Stephen Williamson
Senior Vice President and Chief Financial Officer

EX-32.1

Exhibit 32.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, President and Chief Executive Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  May 4, 2018

/s/ Marc N. Casper

Marc N. Casper

President and Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Williamson, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  May 4, 2018

/s/ Stephen Williamson

Stephen Williamson

Senior Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2018 shares
Document and Entity Information [Abstract]
Entity Registrant Name	Thermo Fisher Scientific Inc.
Entity Central Index Key	0000097745
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	402,323,310
Entity Stock Trading Symbol	TMO

XML

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 950	$ 1,335
Accounts receivable, less allowances of $114 and $109	3,990	3,879
Inventories	2,891	2,971
Refundable income taxes	540	432
Other current assets	1,217	804
Total current assets	9,588	9,421
Property, Plant and Equipment, Net	4,059	4,047
Acquisition-related Intangible Assets, Net	16,393	16,684
Other Assets	1,178	1,227
Goodwill	25,362	25,290
Total Assets	56,580	56,669
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	2,814	2,135
Accounts payable	1,354	1,428
Accrued payroll and employee benefits	643	918
Contract liabilities	909	0
Deferred revenue	0	719
Other accrued expenses	1,352	1,848
Total current liabilities	7,072	7,048
Deferred Income Taxes	2,606	2,766
Other Long-term Liabilities	2,657	2,569
Long-term Obligations	18,122	18,873
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 429,442,440 and 428,327,873 shares issued	429	428
Capital in excess of par value	14,319	14,177
Retained earnings	16,542	15,914
Treasury stock at cost, 27,119,130 and 27,013,311 shares	(3,125)	(3,103)
Accumulated other comprehensive items	(2,042)	(2,003)
Total shareholders' equity	26,123	25,413
Total Liabilities and Shareholders' Equity	$ 56,580	$ 56,669

XML

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 114	$ 109
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	429,442,440	428,327,873
Treasury Stock at Cost (in shares)	27,119,130	27,013,311

XML

Consolidated Statement of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Revenues
Product revenues	$ 4,528	$ 4,102
Service revenues	1,325	663
Total revenues	5,853	4,765
Costs and Operating Expenses:
Cost of product revenues	2,325	2,129
Cost of service revenues	948	443
Selling, general and administrative expenses	1,515	1,334
Research and development expenses	234	215
Restructuring and other costs, net	45	24
Total costs and operating expenses	5,067	4,145
Operating Income	786	620
Other Expense, Net	(152)	(117)
Income Before Income Taxes	634	503
(Provision for) Benefit from Income Taxes	(55)	48
Net Income	$ 579	$ 551
Earnings per Share
Basic (in dollars per share)	$ 1.44	$ 1.41
Diluted (in dollars per share)	$ 1.43	$ 1.40
Weighted Average Shares
Basic (in shares)	402	391
Diluted (in shares)	406	394
Cash Dividends Declared per Common Share (in dollars per share)	$ 0.17	$ 0.15

XML

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Comprehensive Income
Net Income	$ 579	$ 551
Other Comprehensive Items:
Currency translation adjustment (net of tax benefit of $47 and $0)	47	160
Unrealized gains and losses on available-for-sale investments:
Unrealized holding gains arising during the period (net of tax provision of $0 and $0)	0	1
Unrealized gains and losses on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax benefit of $1 and $1)	2	2
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of ($1) and ($1))	(2)	(2)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $1 and $1)	2	2
Total other comprehensive items	49	163
Comprehensive Income	$ 628	$ 714

XML

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ (47)	$ 0
Tax provision (benefit) on unrealized holding gains and losses on available-for-sale investments arising during the period	0	0
Tax provision (benefit) on reclassification adjustment for losses on hedging instruments recognized in net income	(1)	(1)
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period	(1)	(1)
Tax provision (benefit) on amortization of net loss and prior service benefit included in net periodic pension cost	$ (1)	$ (1)

XML

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Operating Activities
Net Income	$ 579	$ 551
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	575	465
Change in deferred income taxes	(121)	(127)
Non-cash stock-based compensation	43	33
Non-cash charges for sale of inventories revalued at the date of acquisition	3	31
Other non-cash expenses, net	24	28
Changes in assets and liabilities, excluding the effects of acquisitions and dispositions:
Accounts receivable	(71)	(18)
Inventories	(124)	(105)
Other assets	(192)	(134)
Accounts payable	(94)	114
Other liabilities	(520)	(303)
Contributions to retirement plans	(24)	(173)
Net cash provided by continuing operations	78	362
Net cash used in discontinued operations	0	(1)
Net cash provided by operating activities	78	361
Investing Activities
Acquisitions, net of cash acquired	(57)	(301)
Purchase of property, plant and equipment	(118)	(93)
Proceeds from sale of property, plant and equipment	2	1
Other investing activities, net	(6)	11
Net cash used in investing activities	(179)	(382)
Financing Activities
Net proceeds from issuance of debt	0	519
Repayment of debt	(453)	(703)
Proceeds from issuance of commercial paper	1,306	2,361
Repayments of commercial paper	(1,124)	(1,795)
Purchases of company common stock	0	(500)
Dividends paid	(60)	(59)
Net proceeds from issuance of company common stock under employee stock plans	39	58
Other financing activities	(50)	0
Net cash used in financing activities	(342)	(119)
Exchange Rate Effect on Cash	57	66
Decrease in Cash, Cash Equivalents and Restricted Cash	(386)	(74)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	1,361	811
Cash, Cash Equivalents and Restricted Cash at End of Period	$ 975	$ 737

XML

Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
Balance (in shares) at Dec. 31, 2016		415			22
Balance at Dec. 31, 2016	$ 21,540	$ 415	$ 12,140	$ 13,927	$ (2,306)	$ (2,636)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		1			0
Issuance of shares under employees' and directors' stock plans	67	$ 1	79		$ (13)
Stock-based compensation	33		33
Purchases of company common stock (in shares)					3
Purchases of company common stock	(500)				$ (500)
Dividends declared	(59)			(59)
Net Income	551			551
Other comprehensive items	163					163
Balance (in shares) at Apr. 01, 2017		416			25
Balance at Apr. 01, 2017	21,795	$ 416	12,252	14,419	$ (2,819)	(2,473)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes	30			118		(88)
Balance (in shares) at Dec. 31, 2017		428			27
Balance at Dec. 31, 2017	25,413	$ 428	14,177	15,914	$ (3,103)	(2,003)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		1			0
Issuance of shares under employees' and directors' stock plans	51	$ 1	72		$ (22)
Stock-based compensation	43		43
Dividends declared	(69)			(69)
Net Income	579			579
Other comprehensive items	49					49
Other	27		27
Balance (in shares) at Mar. 31, 2018		429			27
Balance at Mar. 31, 2018	$ 26,123	$ 429	$ 14,319	$ 16,542	$ (3,125)	$ (2,042)

XML

Nature of Operations and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations and Summary of Significant Accounting Policies [Text Block]

Note 1. Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.

Interim Financial Statements

The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at March 31, 2018, the results of operations for the three-month periods endedMarch 31, 2018 and April 1, 2017, and the cash flows for the three-month periods endedMarch 31, 2018 and April 1, 2017. Interim results are not necessarily indicative of results for a full year.

The consolidated balance sheet presented as of December 31, 2017, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2017 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC).

Note 1 to the consolidated financial statements for 2017 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. Except for the accounting for revenue arising from contracts with customers as noted below there have been no material changes in the company’s significant accounting policies during the three months ended March 31, 2018.

Revenue Recognition

The company recognizes revenue for the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.

Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (clinical trial logistics, pharmaceutical development and manufacturing services, asset management, diagnostic testing, training, service contracts, and field services including related time and materials) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated as inputs to measure progress. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled to each performance obligation based on relative standalone selling prices and recognizes the related revenue when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.

Payments from customers for most instruments, consumables and services are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g. extended service contracts), upon completion of the service (e.g. pharmaceutical development and manufacturing) or a mix of both.

See Note 3 for revenue disaggregated by type and by geographic region as well as further information about remaining performance obligations.

Contract-related Balances

Contract assets include revenues recognized in advance of billings and are recorded net of estimated losses resulting from the inability to invoice customers. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional. Current contract assets and noncurrent contract assets are included within other current assets and other assets, respectively, in the accompanying balance sheet.

Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet.

Contract asset and liability balances are as follows:

	March 31,		January 1,
(In millions)	2018		2018
Current Contract Assets, Net	$	458	$	396
Current Contract Liabilities	909		805
Noncurrent Contract Liabilities	317		302

Noncurrent contract assets were immaterial in 2018. In the first three months of 2018, the company recognized revenue of $308 million that was included in the contract liabilities balance at January 1,2018.

Warranty Obligations

The liability for warranties is included in other accrued expenses in the accompanying balance sheet.The changes in the carrying amount of standard product warranty obligations are as follows:

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Beginning Balance	$	87		$	78
Provision charged to income	31			25
Usage	(28		)	(25		)
Acquisitions	—			1
Adjustments to previously provided warranties, net	(1		)	(1		)
Currency translation	1			1
Ending Balance	$	90		$	79

Inventories

The components of inventories are as follows:

	March 31,		December 31,
(In millions)	2018		2017
Raw Materials	$	776	$	708
Work in Process	402		505
Finished Goods	1,713		1,758
Inventories	$	2,891	$	2,971

Property, Plant and Equipment

Property, plant and equipment consists of the following:

	March 31,		December 31,
(In millions)	2018		2017
Land	$	405	$	401
Buildings and Improvements	1,688		1,662
Machinery, Equipment and Leasehold Improvements	4,427		4,276
Property, Plant and Equipment, at Cost	6,520		6,339
Less: Accumulated Depreciation and Amortization	2,461		2,292
Property, Plant and Equipment, Net	$	4,059	$	4,047

Acquisition-related Intangible Assets

Acquisition-related intangible assets are as follows:

	Balance at March 31, 2018							Balance at December 31, 2017
(In millions)	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Definite Lived:
Customer relationships	$	17,439	$	(6,170	)	$	11,269	$	17,356	$	(5,902	)	$	11,454
Product technology	6,107		(2,953		)	3,154		6,046		(2,811		)	3,235
Tradenames	1,547		(862		)	685		1,538		(817		)	721
Other	35		(35		)	—		34		(34		)	—
	25,128		(10,020		)	15,108		24,974		(9,564		)	15,410
Indefinite Lived:
Tradenames	1,235		N/A			1,235		1,235		N/A			1,235
In-process research and development	50		N/A			50		39		N/A			39
	1,285		N/A			1,285		1,274		N/A			1,274
Acquisition-related Intangible Assets	$	26,413	$	(10,020	)	$	16,393	$	26,248	$	(9,564	)	$	16,684

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2) and the ultimate loss from abandoning leases at facilities being exited (Note 13). Actual results could differ from those estimates.

Recent Accounting Pronouncements

In February 2018, the FASB issued new guidance to allow reclassifications from accumulated other comprehensive items (AOCI) to retained earnings for certain tax effects on items within AOCI resulting from the Tax Cuts and Jobs Act of 2017 (the Tax Act). The company adopted this guidance in January 2018 and recorded the reclassifications in the period of adoption. The balance sheet impact of adopting this guidance is included in the table below. This guidance only relates to the effects of the Tax Act. For all other tax law changes that have occurred or may occur in the future, the company reclassifies the tax effects to the consolidated statement of income on an item-by-item basis when the pre-tax item in AOCI is reclassified to income.

In December 2017, the SEC staff issued guidance to address the application of accounting guidance in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act enacted on December 22, 2017. The company reported provisional amounts in its 2017 financial statements for certain income tax effects of the Tax Act for which a reasonable estimate could be determined but for which the accounting impact may change. For example, these estimates may be impacted by the need for further analysis and future clarification and guidance regarding available tax accounting methods and elections, earnings and profits computations and state tax conformity to federal changes. Adjustments to provisional amounts identified during the measurement period, which may be up to December 22, 2018, will be included as adjustments to Benefit from (Provision for) Income Taxes in the period the amounts are determined.

In August 2017, the FASB issued new guidance to simplify the application of hedge accounting guidance. Among other things, the new guidance will permit more hedging strategies to qualify for hedge accounting, allow for additional time to perform an initial assessment of a hedge’s effectiveness, and permit a qualitative effectiveness test for certain hedges after initial qualification. The company adopted this guidance in January 2018. The balance sheet impact of adopting this guidance is included in the table below.

In March 2017, the FASB issued new guidance intended to improve the presentation of net periodic pension cost and net periodic postretirement benefit cost. The new guidance requires the service cost component of net periodic cost be reported in the same line item(s) as other employee compensation costs and all other components of the net periodic cost be reported in the income statement below operating income. The company adopted this guidance on January 1, 2018 and applied the changes to the statement of income retrospectively. As a result of adoption of this guidance, the accompanying 2017 statement of income reflects the following changes from previously reported amounts:

	Three Months Ended
	April 1,
(In millions)	2017
Increase in Total Costs and Operating Expenses (principally Selling, General and Administrative Expenses)	$	2
Decrease in Operating Income	2
Increase in Other Income (Expense)	2

In January 2017, the FASB issued new guidance clarifying the definition of a business and providing criteria to determine when an integrated set of assets and activities is not defined as a business. The new guidance requires such integrated sets to be defined as an asset (and not a business) if substantially all of the fair value of the gross assets acquired or disposed is concentrated in a single identifiable asset or a group of similar identifiable assets. The adoption of this guidance as of January 1, 2018 did not have a material impact on the company’s consolidated financial statements.

In October 2016, the FASB issued new guidance eliminating the deferral of the tax effects of intra-entity asset transfers. The impact of this guidance in future periods will be dependent on the extent of future asset transfers which usually occur in connection with planning around acquisitions and other business structuring activities. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below.

In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. The company plans to adopt the guidance in 2019 using a modified retrospective method. The company is currently evaluating the impact this guidance will have on its consolidated financial statements, however, assets and liabilities will increase upon adoption for right-of-use assets and lease liabilities. The company’s future commitments under lease obligations are summarized in Note 10 to the consolidated financial statements for 2017 included in the company's Annual Report on Form 10-K, filed with the SEC.

In January 2016, the FASB issued new guidance which affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. This guidance requires equity investments to be measured at fair value with subsequent changes recognized in net income, except for those accounted for under the equity method or requiring consolidation. The guidance also changes the accounting for investments without a readily determinable fair value and that do not qualify for the practical expedient permitted by the guidance to estimate fair value. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below.

In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most previous revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. During 2016 and 2017, the FASB issued additional guidance and clarification, including the elimination of certain SEC Staff Guidance. The guidance is effective for the company in 2018. The company has elected to adopt this guidance through application of the modified retrospective method by applying it to contracts that were not completed as of December 31, 2017 (in addition to new contracts in 2018).

Adoption of new guidance that became effective on January 1, 2018, impacted the company's Consolidated Balance Sheet as follows:

(In millions)	December 31, 2017 as Reported			Impact of Adopting New Revenue Guidance			Impact of Adopting New Equity Investment Guidance			Impact of Adopting New Intra-entity Tax Guidance			Impact of Adopting New Hedge Accounting Guidance			Impact of Adopting New Tax Effects on Items in AOCI Guidance			January 1, 2018 as Adopted
Accounts Receivable, Less Allowances	$	3,879		$	(8	)	$	—		$	—		$	—		$	—		$	3,871
Inventories	2,971			(252		)	—			—			—			—			2,719
Other Current Assets	804			296			—			—			—			—			1,100
Other Assets	1,227			—			—			(77		)	—			—			1,150
Contract Liabilities	—			805			—			—			—			—			805
Deferred Revenue	719			(719		)	—			—			—			—			—
Other Accrued Expenses	1,848			(153		)	—			—			—			—			1,695
Deferred Income Taxes	2,766			—			—			(57		)	—			2			2,711
Other Long-term Liabilities	2,569			54			—			—			—			—			2,623
Long-term Obligations	18,873			—			—			—			(3		)	—			18,870
Retained Earnings	15,914			49			(1		)	(20		)	3			87			16,032
Accumulated Other Comprehensive Items	(2,003		)	—			1			—			—			(89		)	(2,091		)

Had the company continued to use the revenue recognition guidance in effect prior to 2018, no material changes would have resulted to the consolidated statements of income, comprehensive income, or cash flows for the three months endedMarch 31, 2018, from amounts reported therein. However, inventories would have been $280 million higher and other current assets would have been $344 million lower as of March 31, 2018, primarily as a result of differences in the accounting for pharmaceutical development and manufacturing services under the new revenue guidance. Under the prior guidance, costs of these services were recorded in inventory while under the new guidance, costs are expensed as the manufacturing service is performed and the company's rights to consideration are recorded as contract assets and included in other current assets.

XML

Acquisitions

3 Months Ended

Mar. 31, 2018

Business Combinations [Abstract]

Acquisitions and Dispositions [Text Block]

Note 2. Acquisitions

The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.

Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

2018

In 2018, the company acquired, within the Life Sciences Solutions segment, IntegenX Inc., a North America-based provider of a rapid DNA platform for use in forensics and law enforcement applications, for an aggregate purchase price of $65 million.

XML

Revenue

3 Months Ended

Mar. 31, 2018

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

Note 3. Revenue

Disaggregated Revenue

Revenue by type is as follows:

	Three Months Ended
	March 31,
(In millions)	2018
Revenues
Consumables	$	3,111
Instruments	1,416
Services	1,325
Consolidated revenues	$	5,853

Revenue by geographic region is as follows:

	Three Months Ended
	March 31,
(In millions)	2018
Revenues
North America	$	2,903
Europe	1,518
Asia-Pacific	1,264
Other regions	168
Consolidated revenues	$	5,853

Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See note 4 for revenue by reportable segment and other geographic data.

Remaining Performance Obligations

The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of March 31, 2018 was $4.94 billion. The company will recognize revenue for these performance obligations as they are satisfied, the majority of which is expected to occur within the next twelve months.

XML

Business Segment and Geographical Information

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Business Segment and Geographical Information [Text Block]

Note 4. Business Segment and Geographical Information

The company’s financial performance is reported in four segments. A description of each segment follows.

Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.

Analytical Instruments: provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.

Specialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories.

Laboratory Products and Services: provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial and healthcare settings. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical trials logistics and commercial drug manufacturing.

The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.

Business Segment Information

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Revenues
Life Sciences Solutions	$	1,499		$	1,363
Analytical Instruments	1,257			1,052
Specialty Diagnostics	947			866
Laboratory Products and Services	2,413			1,699
Eliminations	(263		)	(215		)
Consolidated revenues	5,853			4,765
Segment Income (a)
Life Sciences Solutions	517			433
Analytical Instruments	246			192
Specialty Diagnostics	243			233
Laboratory Products and Services	280			216
Subtotal reportable segments (a)	1,286			1,074
Cost of revenues charges	(3		)	(31		)
Selling, general and administrative charges, net	(8		)	(31		)
Restructuring and other costs, net	(45		)	(24		)
Amortization of acquisition-related intangible assets	(444		)	(368		)
Consolidated operating income	786			620
Other expense, net (b)	(152		)	(117		)
Income from continuing operations before income taxes	$	634		$	503
Depreciation
Life Sciences Solutions	$	31		$	33
Analytical Instruments	18			17
Specialty Diagnostics	19			17
Laboratory Products and Services	63			30
Consolidated depreciation	$	131		$	97

(a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

(b) The company does not allocate other expense, net to its segments.

Geographical Information

	Three Months Ended
	March 31,		April 1,
(In millions)	2018		2017
Revenues (c)
United States	$	2,756	$	2,377
China	541		441
Other	2,556		1,947
Consolidated revenues	$	5,853	$	4,765

(c) Revenues are attributed to countries based on customer location.

XML

Other Expense, Net

3 Months Ended

Mar. 31, 2018

Other Income and Expenses [Abstract]

Other Expense, Net [Text Block]

Note 5. Other Expense, Net

The components of other expense, net, in the accompanying statement of income are as follows:

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Interest Income	$	20		$	18
Interest Expense	(163		)	(135		)
Other Items, Net	(9		)	—
Other Expense, Net	$	(152	)	$	(117	)

Other Items, Net

In all periods, other items, net includes currency transaction gains and losses on monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income.

XML

Income Taxes

3 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes [Text Block]

Note 6. Income Taxes

The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following:

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Statutory Federal Income Tax Rate	21		%	35		%
Provision for Income Taxes at Statutory Rate	$	133		$	176
Increases (Decreases) Resulting From:
Foreign rate differential	(19		)	(84		)
Income tax credits	(41		)	(41		)
Foreign-derived intangible income	(9		)	—
Singapore tax holiday	(8		)	(5		)
Impact of change in tax laws and apportionment on deferred taxes	3			(63		)
Transition tax and other initial impacts of U.S. tax reform	70			—
Provision of tax reserves, net	(49		)	—
Excess tax benefits from stock options and restricted stock units	(25		)	(24		)
Other, net	—			(7		)
Provision for (benefit from) income taxes	$	55		$	(48	)

The company has operations and a taxable presence in approximately 50 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries.

In the first quarter of 2018, the company recorded a net tax provision of $21 million to adjust the estimated initial impacts of U.S. tax reform recorded in 2017, consisting of an incremental provision of $70 million offset in part by a $49 million reduction of related unrecognized tax benefits established in 2017. The adjustment was required based on new U.S. Treasury guidance released in the first quarter of 2018.

The company has significant activities in Singapore and has received considerable tax incentives. The local taxing authority granted the company pioneer company status which provides an incentive encouraging companies to undertake activities that have the effect of promoting economic or technological development in Singapore. This incentive equates to a tax exemption on earnings associated with most of the company’s manufacturing activities in Singapore and continues through December 31, 2026. In 2018 and 2017, the impact of this tax holiday decreased the annual effective tax rates by 1.3 percentage points and 0.9 percentage point, respectively, and increased diluted earnings per share by approximately $0.02 and $0.01, respectively.

Unrecognized Tax Benefits

As of March 31, 2018, the company had $1.27 billion of unrecognized tax benefits which, if recognized, would reduce the effective tax rate.

A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:

(In millions)	2018
Balance at beginning of year	$	1,409
Reductions due to acquisitions	(9		)
Additions for tax positions of current year	1
Additions for tax positions of prior years	1
Reductions for tax positions of prior years	(84		)
Settlements	(45		)
Balance at end of period	$	1,273

XML

Earnings Per Share

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Note 7. Earnings per Share

	Three Months Ended
	March 31,		April 1,
(In millions except per share amounts)	2018		2017
Net Income	$	579	$	551
Basic Weighted Average Shares	402		391
Plus Effect of:
Stock options and restricted units	4		3
Diluted Weighted Average Shares	406		394
Basic Earnings per Share	$	1.44	$	1.41
Diluted Earnings per Share	$	1.43	$	1.40
Antidilutive Stock Options Excluded from Diluted Weighted Average Shares	2		3

XML

Debt and Other Financing Arrangements

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Debt and Other Financing Arrangements [Text Block]

Note 8. Debt and Other Financing Arrangements

	Effective Interest Rate at March 31,		March 31,			December 31,
(Dollars in millions)	2018		2018			2017
Commercial Paper	—	%	$	1,171		$	960
Floating Rate 2-Year Senior Notes, Due 8/9/2018 (euro-denominated)	0.38	%	739			721
2.15% 3-Year Senior Notes, Due 12/14/2018			—			450
2.40% 5-Year Senior Notes, Due 2/1/2019	2.59	%	900			900
Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated)	0.09	%	616			600
6.00% 10-Year Senior Notes, Due 3/1/2020	2.97	%	750			750
4.70% 10-Year Senior Notes, Due 5/1/2020	4.23	%	300			300
1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated)	1.62	%	524			510
5.00% 10-Year Senior Notes, Due 1/15/2021	3.24	%	400			400
4.50% 10-Year Senior Notes, Due 3/1/2021	6.24	%	1,000			1,000
3.60% 10-Year Senior Notes, Due 8/15/2021	6.06	%	1,100			1,100
3.30% 7-Year Senior Notes, Due 2/15/2022	3.43	%	800			800
2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated)	2.28	%	616			600
3.15% 10-Year Senior Notes, Due 1/15/2023	3.30	%	800			800
3.00% 7-Year Senior Notes, Due 4/15/2023	6.23	%	1,000			1,000
4.15% 10-Year Senior Notes, Due 2/1/2024	4.16	%	1,000			1,000
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)	0.95	%	1,232			1,201
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)	2.10	%	789			768
3.65% 10-Year Senior Notes, Due 12/15/2025	3.77	%	350			350
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)	1.53	%	863			840
2.95% 10-Year Senior Notes, Due 9/19/2026	3.19	%	1,200			1,200
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)	1.67	%	616			600
3.20% 10-Year Senior Notes, Due 8/15/2027	3.39	%	750			750
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)	1.46	%	739			721
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)	2.08	%	863			840
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)	2.94	%	863			840
5.30% 30-Year Senior Notes, Due 2/1/2044	5.37	%	400			400
4.10% 30-Year Senior Notes, Due 8/15/2047	4.32	%	750			750
Other			23			24
Total Borrowings at Par Value			21,154			21,175
Fair Value Hedge Accounting Adjustments			(120		)	(70		)
Unamortized Discount, Net			(8		)	(2		)
Unamortized Debt Issuance Costs			(90		)	(95		)
Total Borrowings at Carrying Value			20,936			21,008
Less: Short-term Obligations and Current Maturities			2,814			2,135
Long-term Obligations			$	18,122		$	18,873

The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium, the amortization of any debt issuance costs and, if applicable, adjustments related to hedging.

See Note 11 for fair value information pertaining to the company’s long-term obligations.

Credit Facilities

The company has a revolving credit facility with a bank group that provides for up to $2.50 billion of unsecured multi-currency revolving credit. The facility expires in July 2021. The agreement calls for interest at either a LIBOR-based rate, a EURIBOR-based rate (for funds drawn in Euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in our revolving credit facility (the Facility) include a Consolidated Leverage Ratio (total debt-to-Consolidated EBITDA) and a Consolidated Interest Coverage Ratio (Consolidated EBITDA to Consolidated Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a maximum Consolidated Leverage Ratio of 4.0:1.0 through the second quarter of 2018 and then stepping down to 3.5:1.0 for the third quarter of 2018 and thereafter. The company has also agreed that so long as any lender has any commitment under the Facility or any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.0:1.0 as of the last day of any fiscal quarter. As of March 31, 2018, no borrowings were outstanding under the Facility, although available capacity was reduced by approximately $75 million as a result of outstanding letters of credit.

Commercial Paper Programs

The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of March 31, 2018, outstanding borrowings under these programs were $1.17 billion, with a weighted average remaining period to maturity of 50 days and are classified as short-term obligations in the accompanying balance sheet.

Senior Notes

Interest on the floating rate senior notes is payable quarterly. Interest is payable annually on the other euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements.

Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the company issued the Floating Rate Senior Notes due 2018 included in the table above. This subsidiary has no independent function other than financing activities. The Floating Rate Senior Notes due 2018 are fully and unconditionally guaranteed by the company and no other subsidiaries of the company have guaranteed the obligations.

Interest Rate Swap Arrangements

The company has entered into LIBOR-based interest rate swap arrangements with various banks on several of its outstanding senior notes. The aggregate amounts of the swaps are equal to the principal amounts of the notes and the payment dates of the swaps coincide with the interest payment dates of the notes. The swap contracts provide for the company to pay a variable interest rate and receive a fixed rate. The variable interest rates reset monthly. The swaps have been accounted for as fair value hedges of the notes. See Note 11 for additional information. The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at March 31, 2018:

	Aggregate Notional Amount		Pay Rate as of
(Dollars in millions)		Pay Rate	March 31, 2018		Receive Rate
4.50% Senior Notes due 2021	1,000	1-month LIBOR + 3.4420%	5.1062	%	4.50	%
3.60% Senior Notes due 2021	1,100	1-month LIBOR + 2.5150%	4.2916	%	3.60	%
3.00% Senior Notes due 2023	1,000	1-month LIBOR + 1.7640%	3.5406	%	3.00	%

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies [Text Block]

Note 9. Commitments and Contingencies

Environmental Matters

The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At March 31, 2018, the company’s total environmental liability was approximately $61 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows.

Litigation and Related Contingencies

There are various lawsuits and claims pending against the company including matters involving product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below or in the company's 2017 financial statements and notes included in the company's Annual Report on Form 10-K filed with the SEC, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows.

Product Liability, Workers Compensation and Other Personal Injury Matters

For product liability, workers compensation and other personal injury matters, the company accrues the most likely amount or at least the minimum of the range of possible loss when a range of possible loss can be estimated. The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.

Intellectual Property Matters

On May 26, 2010, Promega Corp. & Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften EV filed a complaint against Life Technologies in the United States District Court for the Western District of Wisconsin. The plaintiffs allege patent infringement by sales and uses of Applied Biosystems’ short tandem repeat DNA identification products outside the scope of a 2006 license agreement. The plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief. Although a jury initially found willful infringement and assessed damages at $52 million the District Court subsequently overturned the verdict on the grounds that the plaintiff had failed to prove infringement. The District Court entered judgment in favor of Life Technologies; and plaintiffs and Life Technologies filed cross-appeals with the United States Court of Appeals for the Federal Circuit. The $52 million award was accrued by Life Technologies and the liability was assumed by the company as of the date of the acquisition. On December 15, 2014, the Court of Appeals issued a decision invalidating four of the plaintiffs’ patents, but finding infringement by Life Technologies of the remaining fifth patent. The Court of Appeals also ordered a new trial on damages in the District Court. Life Technologies' petition to the U.S. Supreme Court seeking review of the Court of Appeals’ judgment was granted on June 27, 2016, and the case was stayed in the District Court pending the outcome of the Supreme Court’s review. On February 22, 2017, the Supreme Court issued a decision reversing the Court of Appeals’ judgment and remanding the case to the Court of Appeals for further proceedings in view of the Supreme Court’s legal interpretation of the patent law statute in question. On November 13, 2017, the Court of Appeals issued a decision holding that Promega is not entitled to recover any damages and affirming the District Court’s grant of judgment in favor of Life Technologies and denial of Promega’s motion for a new trial. The Court of Appeals denied Promega’s petition for rehearing on February 14, 2018, and Promega has 90 days therefrom to file a petition with the U.S. Supreme Court seeking review of the Court of Appeals' decision. The company has maintained the $52 million accrual, pending conclusion of this matter.

On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product "supply centers" installed at customer sites. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief. On August 24, 2017, Unisone filed an appeal from a decision by the Patent Trial and Appeal Board that found the challenged patent claims invalid.

XML

Comprehensive Income and Shareholders Equity

3 Months Ended

Mar. 31, 2018

Stockholders' Equity Note [Abstract]

Comprehensive Income and Shareholders' Equity [Text Block]

Note 10. Comprehensive Income and Shareholders' Equity

Comprehensive Income (Loss)

Comprehensive income (loss) combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet.

Changes in each component of accumulated other comprehensive items, net of tax are as follows: 

(In millions)	Currency Translation Adjustment			Unrealized Losses on Available-for- Sale Investments			Unrealized Losses on Hedging Instruments			Pension and Other Postretirement Benefit Liability Adjustment			Total
Balance at December 31, 2017	$	(1,755	)	$	(1	)	$	(50	)	$	(197	)	$	(2,003	)
Cumulative effect of accounting changes (Note 1)	(54		)	1			(11		)	(24		)	(88		)
Other comprehensive income (loss) before reclassifications	47			—			—			(2		)	45
Amounts reclassified from accumulated other comprehensive items	—			—			2			2			4
Net other comprehensive items	47			—			2			—			49
Balance at March 31, 2018	$	(1,762	)	$	—		$	(59	)	$	(221	)	$	(2,042	)

XML

Fair Value Measurements and Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements and Fair Value of Financial Instruments [Text Block]

Note 11. Fair Value Measurements and Fair Value of Financial Instruments

Fair Value Measurements

The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2018. The company’s financial assets and liabilities carried at fair value are primarily comprised of insurance contracts, investments in money market funds, derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.

Level 3: Inputs are unobservable data points that are not corroborated by market data.

The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2018 and December 31, 2017:

	March 31,		Quoted Prices in Active Markets		Significant Other Observable  Inputs		Significant Unobservable Inputs
(In millions)	2018		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	36	$	36	$	—	$	—
Bank time deposits	2		2		—		—
Investments in mutual funds and other similar instruments	13		13		—		—
Warrants	2		—		2		—
Insurance contracts	115		—		115		—
Derivative contracts	7		—		7		—
Total Assets	$	175	$	51	$	124	$	—
Liabilities
Derivative contracts	$	165	$	—	$	165	$	—
Contingent consideration	41		—		—		41
Total Liabilities	$	206	$	—	$	165	$	41

	December 31,		Quoted Prices in  Active Markets		Significant Other Observable  Inputs		Significant  Unobservable  Inputs
(In millions)	2017		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	22	$	22	$	—	$	—
Bank time deposits	2		2		—		—
Investments in mutual funds and other similar instruments	13		13		—		—
Warrants	2		—		2		—
Insurance contracts	116		—		116		—
Derivative contracts	10		—		10		—
Total Assets	$	165	$	37	$	128	$	—
Liabilities
Derivative contracts	$	139	$	—	$	139	$	—
Contingent consideration	35		—		—		35
Total Liabilities	$	174	$	—	$	139	$	35

The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determines the fair value of acquisition-related contingent consideration based on the probability-weighted discounted cash flows associated with such future payments. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration.

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Contingent Consideration
Beginning Balance	$	35		$	6
Acquisitions	11			9
Payments	(5		)	—
Change in fair value included in earnings	—			25
Ending Balance	$	41		$	40

Derivative Contracts

As of both March 31, 2018 and December 31, 2017, the total notional amount of outstanding interest rate swaps was $3.10 billion. These swap arrangements are described in Note 8. The notional amounts of currency exchange contracts outstanding totaled $2.98 billion and $2.92 billion at March 31, 2018 and December 31, 2017, respectively.

While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income.

	Fair Value – Assets				Fair Value – Liabilities
	March 31,		December 31,		March 31,		December 31,
(In millions)	2018		2017		2018		2017
Derivatives Designated as Hedging Instruments
Interest rate swaps (a)	$	—	$	—	$	162	$	124
Derivatives Not Designated as Hedging Instruments
Currency exchange contracts (b)	7		10		3		15
Total Derivatives	$	7	$	10	$	165	$	139

(a) The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities.

(b) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses.

The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations:

	Carrying Amount of the Hedged Liability				Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability (c)
	March 31,		December 31,		March 31,			December 31,
(In millions)	2018		2017		2018			2017
Long-term Obligations	$	3,261	$	3,309	$	(120	)	$	(70	)

(c) Includes increases in the carrying amount of $40 million and $43 million at March 31, 2018 and December 31, 2017, respectively, on discontinued hedging relationships.

	Gain (Loss) Recognized
	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Fair Value Hedging Relationships
Interest rate swaps
Hedged long-term obligations - included in other expense, net	$	(38	)	$	(6	)
Derivatives designated as hedging instruments - included in other expense, net	42			3
Derivatives Designated as Cash Flow Hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to other expense, net	(3		)	(3		)
Derivatives Designated as Net Investment Hedges
Foreign currency-denominated debt
Included in currency translation adjustment within other comprehensive items	(200		)	(46		)
Derivatives Not Designated as Hedging Instruments
Currency exchange contracts
Included in cost of revenues	(2		)	(1		)
Included in other expense, net	(8		)	19

Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.

The company uses foreign currency-denominated debt to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The company’s euro-denominated senior notes have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in currency translation adjustment within other comprehensive items and shareholders’ equity.

See Note 1 to the consolidated financial statements for 2017 included in the company's Annual Report on Form 10-K for additional information on the company's risk management objectives and strategies.

Fair Value of Other Financial Instruments

The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:

	March 31, 2018				December 31, 2017
	Carrying		Fair		Carrying		Fair
(In millions)	Value		Value		Value		Value
Notes Receivable	$	94	$	99	$	89	$	93
Debt Obligations:
Senior notes	$	19,742	$	20,053	$	20,024	$	20,639
Commercial paper	1,171		1,171		960		960
Other	23		23		24		24
	$	20,936	$	21,247	$	21,008	$	21,623

The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

XML

Supplemental Cash Flow Information

3 Months Ended

Mar. 31, 2018

Supplemental Cash Flow Information [Abstract]

Supplemental Cash Flow Information [Text Block]

Note 12. Supplemental Cash Flow Information

	Three Months Ended
	March 31,		April 1,
(In millions)	2018		2017
Non-cash Investing and Financing Activities
Declared but unpaid dividends	$	69	$	60
Issuance of stock upon vesting of restricted stock units	61		34

Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:

	March 31,		December 31,
(In millions)	2018		2017
Cash and Cash Equivalents	$	950	$	1,335
Restricted Cash Included in Other Current Assets	23		24
Restricted Cash Included in Other Assets	2		2
Cash, Cash Equivalents and Restricted Cash	$	975	$	1,361

Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

XML

Restructuring and Other Costs, Net

3 Months Ended

Mar. 31, 2018

Restructuring and Related Activities [Abstract]

Restructuring and Other Costs, Net [Text Block]

Note 13. Restructuring and Other Costs, Net

Restructuring and other costs in the first three months of 2018 included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S. and Europe; third-party transaction/integration costs related to the acquisition of Patheon; sales of inventories revalued at the date of acquisition; and net charges for litigation matters. In the first three months of 2018, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.

As of May 4, 2018, the company has identified restructuring actions that will result in additional charges of approximately $105 million, primarily in 2018 and 2019, which will be recorded when specified criteria are met, such as communication of benefit arrangements and abandonment of leased facilities.

First Quarter of 2018

During the first quarter of 2018, the company recorded net restructuring and other costs by segment as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs, Net		Total
Life Sciences Solutions	$	—	$	—	$	13	$	13
Analytical Instruments	—		—		17		17
Specialty Diagnostics	—		—		4		4
Laboratory Products and Services	3		7		10		20
Corporate	—		1		1		2
	$	3	$	8	$	45	$	56

The principal components of net restructuring and other costs by segment are as follows:

Life Sciences Solutions

In the first quarter of 2018, the Life Sciences Solutions segment recorded $13 million of net restructuring and other charges, principally charges for litigation-related matters and severance due to employees of an acquired business at the date of acquisition.

Analytical Instruments

In the first quarter of 2018, the Analytical Instruments segment recorded $17 million of net restructuring and other charges, primarily abandoned facilities costs associated with the remediation and closure of a manufacturing facility in the U.S.

Specialty Diagnostics

In the first quarter of 2018, the Specialty Diagnostics segment recorded $4 million of net restructuring and other charges for severance and other costs associated with facility consolidations in the U.S. and Europe.

Laboratory Products and Services

In the first quarter of 2018, the Laboratory Products and Services segment recorded $20 million of net restructuring and other charges. The segment recorded $3 million of charges to cost of revenues for sales of inventories revalued at the date of acquisition, as well as $7 million of charges to selling, general, and administrative expenses for third-party transaction/integration costs related to the acquisition of Patheon. The segment also recorded $10 million of restructuring and other costs, primarily for employee severance, as well as hurricane response costs.

Corporate

In the first quarter of 2018, the company's corporate operations recorded $2 million of net restructuring and other charges primarily for severance.

The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.

(In millions)	Severance			Abandonment of Excess Facilities			Other (a)			Total
Balance at December 31, 2017	$	30		$	40		$	6		$	76
Costs incurred in 2018 (c)	19			16			4			39
Reserves reversed (b)	(3		)	(1		)	—			(4		)
Payments	(10		)	(8		)	(5		)	(23		)
Balance at March 31, 2018	$	36		$	47		$	5		$	88

(a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

(b) Represents reductions in cost of plans.

(c) Excludes $10 million of charges, net, primarily associated with litigation-related matters, hurricane response costs, and non-cash compensation due at an acquired business.

The company expects to pay accrued restructuring costs as follows: severance, employee-retention obligations and other costs, primarily through 2018; and abandoned-facility payments, over lease terms expiring through 2027.

XML

Nature of Operations and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The company recognizes revenue for the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.

Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (clinical trial logistics, pharmaceutical development and manufacturing services, asset management, diagnostic testing, training, service contracts, and field services including related time and materials) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated as inputs to measure progress. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled to each performance obligation based on relative standalone selling prices and recognizes the related revenue when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.

Payments from customers for most instruments, consumables and services are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g. extended service contracts), upon completion of the service (e.g. pharmaceutical development and manufacturing) or a mix of both.

Use of Estimates [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2) and the ultimate loss from abandoning leases at facilities being exited (Note 13). Actual results could differ from those estimates.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

In February 2018, the FASB issued new guidance to allow reclassifications from accumulated other comprehensive items (AOCI) to retained earnings for certain tax effects on items within AOCI resulting from the Tax Cuts and Jobs Act of 2017 (the Tax Act). The company adopted this guidance in January 2018 and recorded the reclassifications in the period of adoption. The balance sheet impact of adopting this guidance is included in the table below. This guidance only relates to the effects of the Tax Act. For all other tax law changes that have occurred or may occur in the future, the company reclassifies the tax effects to the consolidated statement of income on an item-by-item basis when the pre-tax item in AOCI is reclassified to income.

In December 2017, the SEC staff issued guidance to address the application of accounting guidance in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act enacted on December 22, 2017. The company reported provisional amounts in its 2017 financial statements for certain income tax effects of the Tax Act for which a reasonable estimate could be determined but for which the accounting impact may change. For example, these estimates may be impacted by the need for further analysis and future clarification and guidance regarding available tax accounting methods and elections, earnings and profits computations and state tax conformity to federal changes. Adjustments to provisional amounts identified during the measurement period, which may be up to December 22, 2018, will be included as adjustments to Benefit from (Provision for) Income Taxes in the period the amounts are determined.

In August 2017, the FASB issued new guidance to simplify the application of hedge accounting guidance. Among other things, the new guidance will permit more hedging strategies to qualify for hedge accounting, allow for additional time to perform an initial assessment of a hedge’s effectiveness, and permit a qualitative effectiveness test for certain hedges after initial qualification. The company adopted this guidance in January 2018. The balance sheet impact of adopting this guidance is included in the table below.

In March 2017, the FASB issued new guidance intended to improve the presentation of net periodic pension cost and net periodic postretirement benefit cost. The new guidance requires the service cost component of net periodic cost be reported in the same line item(s) as other employee compensation costs and all other components of the net periodic cost be reported in the income statement below operating income. The company adopted this guidance on January 1, 2018 and applied the changes to the statement of income retrospectively. As a result of adoption of this guidance, the accompanying 2017 statement of income reflects the following changes from previously reported amounts:

	Three Months Ended
	April 1,
(In millions)	2017
Increase in Total Costs and Operating Expenses (principally Selling, General and Administrative Expenses)	$	2
Decrease in Operating Income	2
Increase in Other Income (Expense)	2

In January 2017, the FASB issued new guidance clarifying the definition of a business and providing criteria to determine when an integrated set of assets and activities is not defined as a business. The new guidance requires such integrated sets to be defined as an asset (and not a business) if substantially all of the fair value of the gross assets acquired or disposed is concentrated in a single identifiable asset or a group of similar identifiable assets. The adoption of this guidance as of January 1, 2018 did not have a material impact on the company’s consolidated financial statements.

In October 2016, the FASB issued new guidance eliminating the deferral of the tax effects of intra-entity asset transfers. The impact of this guidance in future periods will be dependent on the extent of future asset transfers which usually occur in connection with planning around acquisitions and other business structuring activities. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below.

In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. The company plans to adopt the guidance in 2019 using a modified retrospective method. The company is currently evaluating the impact this guidance will have on its consolidated financial statements, however, assets and liabilities will increase upon adoption for right-of-use assets and lease liabilities. The company’s future commitments under lease obligations are summarized in Note 10 to the consolidated financial statements for 2017 included in the company's Annual Report on Form 10-K, filed with the SEC.

In January 2016, the FASB issued new guidance which affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. This guidance requires equity investments to be measured at fair value with subsequent changes recognized in net income, except for those accounted for under the equity method or requiring consolidation. The guidance also changes the accounting for investments without a readily determinable fair value and that do not qualify for the practical expedient permitted by the guidance to estimate fair value. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below.

In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most previous revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. During 2016 and 2017, the FASB issued additional guidance and clarification, including the elimination of certain SEC Staff Guidance. The guidance is effective for the company in 2018. The company has elected to adopt this guidance through application of the modified retrospective method by applying it to contracts that were not completed as of December 31, 2017 (in addition to new contracts in 2018).

Adoption of new guidance that became effective on January 1, 2018, impacted the company's Consolidated Balance Sheet as follows:

(In millions)	December 31, 2017 as Reported			Impact of Adopting New Revenue Guidance			Impact of Adopting New Equity Investment Guidance			Impact of Adopting New Intra-entity Tax Guidance			Impact of Adopting New Hedge Accounting Guidance			Impact of Adopting New Tax Effects on Items in AOCI Guidance			January 1, 2018 as Adopted
Accounts Receivable, Less Allowances	$	3,879		$	(8	)	$	—		$	—		$	—		$	—		$	3,871
Inventories	2,971			(252		)	—			—			—			—			2,719
Other Current Assets	804			296			—			—			—			—			1,100
Other Assets	1,227			—			—			(77		)	—			—			1,150
Contract Liabilities	—			805			—			—			—			—			805
Deferred Revenue	719			(719		)	—			—			—			—			—
Other Accrued Expenses	1,848			(153		)	—			—			—			—			1,695
Deferred Income Taxes	2,766			—			—			(57		)	—			2			2,711
Other Long-term Liabilities	2,569			54			—			—			—			—			2,623
Long-term Obligations	18,873			—			—			—			(3		)	—			18,870
Retained Earnings	15,914			49			(1		)	(20		)	3			87			16,032
Accumulated Other Comprehensive Items	(2,003		)	—			1			—			—			(89		)	(2,091		)

Had the company continued to use the revenue recognition guidance in effect prior to 2018, no material changes would have resulted to the consolidated statements of income, comprehensive income, or cash flows for the three months endedMarch 31, 2018, from amounts reported therein. However, inventories would have been $280 million higher and other current assets would have been $344 million lower as of March 31, 2018, primarily as a result of differences in the accounting for pharmaceutical development and manufacturing services under the new revenue guidance. Under the prior guidance, costs of these services were recorded in inventory while under the new guidance, costs are expensed as the manufacturing service is performed and the company's rights to consideration are recorded as contract assets and included in other current assets.

Business Combinations Policy [Policy Text Block]

The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.

Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

XML

Acquisitions (Policies)

3 Months Ended

Mar. 31, 2018

Business Combinations [Abstract]

Business Combinations Policy [Policy Text Block]

The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.

Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

XML

Nature of Operations and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Contract with Customer, Asset and Liability [Table Text Block]

Contract asset and liability balances are as follows:

	March 31,		January 1,
(In millions)	2018		2018
Current Contract Assets, Net	$	458	$	396
Current Contract Liabilities	909		805
Noncurrent Contract Liabilities	317		302

Warranty Obligations [Table Text Block]

Warranty Obligations

The liability for warranties is included in other accrued expenses in the accompanying balance sheet.The changes in the carrying amount of standard product warranty obligations are as follows:

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Beginning Balance	$	87		$	78
Provision charged to income	31			25
Usage	(28		)	(25		)
Acquisitions	—			1
Adjustments to previously provided warranties, net	(1		)	(1		)
Currency translation	1			1
Ending Balance	$	90		$	79

Inventories [Table Text Block]

Inventories

The components of inventories are as follows:

	March 31,		December 31,
(In millions)	2018		2017
Raw Materials	$	776	$	708
Work in Process	402		505
Finished Goods	1,713		1,758
Inventories	$	2,891	$	2,971

Property, Plant and Equipment [Table Text Block]

Property, Plant and Equipment

Property, plant and equipment consists of the following:

	March 31,		December 31,
(In millions)	2018		2017
Land	$	405	$	401
Buildings and Improvements	1,688		1,662
Machinery, Equipment and Leasehold Improvements	4,427		4,276
Property, Plant and Equipment, at Cost	6,520		6,339
Less: Accumulated Depreciation and Amortization	2,461		2,292
Property, Plant and Equipment, Net	$	4,059	$	4,047

Finite-Lived Acquisition-related Intangible Assets [Table Text Block]

Acquisition-related Intangible Assets

Acquisition-related intangible assets are as follows:

	Balance at March 31, 2018							Balance at December 31, 2017
(In millions)	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Definite Lived:
Customer relationships	$	17,439	$	(6,170	)	$	11,269	$	17,356	$	(5,902	)	$	11,454
Product technology	6,107		(2,953		)	3,154		6,046		(2,811		)	3,235
Tradenames	1,547		(862		)	685		1,538		(817		)	721
Other	35		(35		)	—		34		(34		)	—
	25,128		(10,020		)	15,108		24,974		(9,564		)	15,410
Indefinite Lived:
Tradenames	1,235		N/A			1,235		1,235		N/A			1,235
In-process research and development	50		N/A			50		39		N/A			39
	1,285		N/A			1,285		1,274		N/A			1,274
Acquisition-related Intangible Assets	$	26,413	$	(10,020	)	$	16,393	$	26,248	$	(9,564	)	$	16,684

Indefinite-Lived Acquisition-related Intangible Assets [Table Text Block]

Acquisition-related Intangible Assets

Acquisition-related intangible assets are as follows:

	Balance at March 31, 2018							Balance at December 31, 2017
(In millions)	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Definite Lived:
Customer relationships	$	17,439	$	(6,170	)	$	11,269	$	17,356	$	(5,902	)	$	11,454
Product technology	6,107		(2,953		)	3,154		6,046		(2,811		)	3,235
Tradenames	1,547		(862		)	685		1,538		(817		)	721
Other	35		(35		)	—		34		(34		)	—
	25,128		(10,020		)	15,108		24,974		(9,564		)	15,410
Indefinite Lived:
Tradenames	1,235		N/A			1,235		1,235		N/A			1,235
In-process research and development	50		N/A			50		39		N/A			39
	1,285		N/A			1,285		1,274		N/A			1,274
Acquisition-related Intangible Assets	$	26,413	$	(10,020	)	$	16,393	$	26,248	$	(9,564	)	$	16,684

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

Adoption of new guidance that became effective on January 1, 2018, impacted the company's Consolidated Balance Sheet as follows:

(In millions)	December 31, 2017 as Reported			Impact of Adopting New Revenue Guidance			Impact of Adopting New Equity Investment Guidance			Impact of Adopting New Intra-entity Tax Guidance			Impact of Adopting New Hedge Accounting Guidance			Impact of Adopting New Tax Effects on Items in AOCI Guidance			January 1, 2018 as Adopted
Accounts Receivable, Less Allowances	$	3,879		$	(8	)	$	—		$	—		$	—		$	—		$	3,871
Inventories	2,971			(252		)	—			—			—			—			2,719
Other Current Assets	804			296			—			—			—			—			1,100
Other Assets	1,227			—			—			(77		)	—			—			1,150
Contract Liabilities	—			805			—			—			—			—			805
Deferred Revenue	719			(719		)	—			—			—			—			—
Other Accrued Expenses	1,848			(153		)	—			—			—			—			1,695
Deferred Income Taxes	2,766			—			—			(57		)	—			2			2,711
Other Long-term Liabilities	2,569			54			—			—			—			—			2,623
Long-term Obligations	18,873			—			—			—			(3		)	—			18,870
Retained Earnings	15,914			49			(1		)	(20		)	3			87			16,032
Accumulated Other Comprehensive Items	(2,003		)	—			1			—			—			(89		)	(2,091		)

	Three Months Ended
	April 1,
(In millions)	2017
Increase in Total Costs and Operating Expenses (principally Selling, General and Administrative Expenses)	$	2
Decrease in Operating Income	2
Increase in Other Income (Expense)	2

XML

Revenue (Tables)

3 Months Ended

Mar. 31, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

Disaggregated Revenue

Revenue by type is as follows:

	Three Months Ended
	March 31,
(In millions)	2018
Revenues
Consumables	$	3,111
Instruments	1,416
Services	1,325
Consolidated revenues	$	5,853

Revenue by geographic region is as follows:

	Three Months Ended
	March 31,
(In millions)	2018
Revenues
North America	$	2,903
Europe	1,518
Asia-Pacific	1,264
Other regions	168
Consolidated revenues	$	5,853

XML

Business Segment and Geographical Information (Tables)

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Business Segment Information

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Revenues
Life Sciences Solutions	$	1,499		$	1,363
Analytical Instruments	1,257			1,052
Specialty Diagnostics	947			866
Laboratory Products and Services	2,413			1,699
Eliminations	(263		)	(215		)
Consolidated revenues	5,853			4,765
Segment Income (a)
Life Sciences Solutions	517			433
Analytical Instruments	246			192
Specialty Diagnostics	243			233
Laboratory Products and Services	280			216
Subtotal reportable segments (a)	1,286			1,074
Cost of revenues charges	(3		)	(31		)
Selling, general and administrative charges, net	(8		)	(31		)
Restructuring and other costs, net	(45		)	(24		)
Amortization of acquisition-related intangible assets	(444		)	(368		)
Consolidated operating income	786			620
Other expense, net (b)	(152		)	(117		)
Income from continuing operations before income taxes	$	634		$	503
Depreciation
Life Sciences Solutions	$	31		$	33
Analytical Instruments	18			17
Specialty Diagnostics	19			17
Laboratory Products and Services	63			30
Consolidated depreciation	$	131		$	97

(a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

(b) The company does not allocate other expense, net to its segments.

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

Business Segment Information

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Revenues
Life Sciences Solutions	$	1,499		$	1,363
Analytical Instruments	1,257			1,052
Specialty Diagnostics	947			866
Laboratory Products and Services	2,413			1,699
Eliminations	(263		)	(215		)
Consolidated revenues	5,853			4,765
Segment Income (a)
Life Sciences Solutions	517			433
Analytical Instruments	246			192
Specialty Diagnostics	243			233
Laboratory Products and Services	280			216
Subtotal reportable segments (a)	1,286			1,074
Cost of revenues charges	(3		)	(31		)
Selling, general and administrative charges, net	(8		)	(31		)
Restructuring and other costs, net	(45		)	(24		)
Amortization of acquisition-related intangible assets	(444		)	(368		)
Consolidated operating income	786			620
Other expense, net (b)	(152		)	(117		)
Income from continuing operations before income taxes	$	634		$	503
Depreciation
Life Sciences Solutions	$	31		$	33
Analytical Instruments	18			17
Specialty Diagnostics	19			17
Laboratory Products and Services	63			30
Consolidated depreciation	$	131		$	97

(a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

(b) The company does not allocate other expense, net to its segments.

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

Geographical Information

	Three Months Ended
	March 31,		April 1,
(In millions)	2018		2017
Revenues (c)
United States	$	2,756	$	2,377
China	541		441
Other	2,556		1,947
Consolidated revenues	$	5,853	$	4,765

(c) Revenues are attributed to countries based on customer location.

XML

Other Expense, Net (Tables)

3 Months Ended

Mar. 31, 2018

Other Income and Expenses [Abstract]

Schedule of Other Nonoperating Income (Expense) [Table Text Block]

The components of other expense, net, in the accompanying statement of income are as follows:

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Interest Income	$	20		$	18
Interest Expense	(163		)	(135		)
Other Items, Net	(9		)	—
Other Expense, Net	$	(152	)	$	(117	)

XML

Income Taxes (Tables)

3 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following:

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Statutory Federal Income Tax Rate	21		%	35		%
Provision for Income Taxes at Statutory Rate	$	133		$	176
Increases (Decreases) Resulting From:
Foreign rate differential	(19		)	(84		)
Income tax credits	(41		)	(41		)
Foreign-derived intangible income	(9		)	—
Singapore tax holiday	(8		)	(5		)
Impact of change in tax laws and apportionment on deferred taxes	3			(63		)
Transition tax and other initial impacts of U.S. tax reform	70			—
Provision of tax reserves, net	(49		)	—
Excess tax benefits from stock options and restricted stock units	(25		)	(24		)
Other, net	—			(7		)
Provision for (benefit from) income taxes	$	55		$	(48	)

Summary of Income Tax Contingencies [Table Text Block]

A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:

(In millions)	2018
Balance at beginning of year	$	1,409
Reductions due to acquisitions	(9		)
Additions for tax positions of current year	1
Additions for tax positions of prior years	1
Reductions for tax positions of prior years	(84		)
Settlements	(45		)
Balance at end of period	$	1,273

XML

Earnings per Share (Tables)

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended
	March 31,		April 1,
(In millions except per share amounts)	2018		2017
Net Income	$	579	$	551
Basic Weighted Average Shares	402		391
Plus Effect of:
Stock options and restricted units	4		3
Diluted Weighted Average Shares	406		394
Basic Earnings per Share	$	1.44	$	1.41
Diluted Earnings per Share	$	1.43	$	1.40
Antidilutive Stock Options Excluded from Diluted Weighted Average Shares	2		3

XML

Debt and Other Financing Arrangements (Tables)

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

	Effective Interest Rate at March 31,		March 31,			December 31,
(Dollars in millions)	2018		2018			2017
Commercial Paper	—	%	$	1,171		$	960
Floating Rate 2-Year Senior Notes, Due 8/9/2018 (euro-denominated)	0.38	%	739			721
2.15% 3-Year Senior Notes, Due 12/14/2018			—			450
2.40% 5-Year Senior Notes, Due 2/1/2019	2.59	%	900			900
Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated)	0.09	%	616			600
6.00% 10-Year Senior Notes, Due 3/1/2020	2.97	%	750			750
4.70% 10-Year Senior Notes, Due 5/1/2020	4.23	%	300			300
1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated)	1.62	%	524			510
5.00% 10-Year Senior Notes, Due 1/15/2021	3.24	%	400			400
4.50% 10-Year Senior Notes, Due 3/1/2021	6.24	%	1,000			1,000
3.60% 10-Year Senior Notes, Due 8/15/2021	6.06	%	1,100			1,100
3.30% 7-Year Senior Notes, Due 2/15/2022	3.43	%	800			800
2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated)	2.28	%	616			600
3.15% 10-Year Senior Notes, Due 1/15/2023	3.30	%	800			800
3.00% 7-Year Senior Notes, Due 4/15/2023	6.23	%	1,000			1,000
4.15% 10-Year Senior Notes, Due 2/1/2024	4.16	%	1,000			1,000
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)	0.95	%	1,232			1,201
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)	2.10	%	789			768
3.65% 10-Year Senior Notes, Due 12/15/2025	3.77	%	350			350
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)	1.53	%	863			840
2.95% 10-Year Senior Notes, Due 9/19/2026	3.19	%	1,200			1,200
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)	1.67	%	616			600
3.20% 10-Year Senior Notes, Due 8/15/2027	3.39	%	750			750
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)	1.46	%	739			721
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)	2.08	%	863			840
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)	2.94	%	863			840
5.30% 30-Year Senior Notes, Due 2/1/2044	5.37	%	400			400
4.10% 30-Year Senior Notes, Due 8/15/2047	4.32	%	750			750
Other			23			24
Total Borrowings at Par Value			21,154			21,175
Fair Value Hedge Accounting Adjustments			(120		)	(70		)
Unamortized Discount, Net			(8		)	(2		)
Unamortized Debt Issuance Costs			(90		)	(95		)
Total Borrowings at Carrying Value			20,936			21,008
Less: Short-term Obligations and Current Maturities			2,814			2,135
Long-term Obligations			$	18,122		$	18,873

Schedule of Derivative Instruments [Table Text Block]

The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at March 31, 2018:

	Aggregate Notional Amount		Pay Rate as of
(Dollars in millions)		Pay Rate	March 31, 2018		Receive Rate
4.50% Senior Notes due 2021	1,000	1-month LIBOR + 3.4420%	5.1062	%	4.50	%
3.60% Senior Notes due 2021	1,100	1-month LIBOR + 2.5150%	4.2916	%	3.60	%
3.00% Senior Notes due 2023	1,000	1-month LIBOR + 1.7640%	3.5406	%	3.00	%

XML

Comprehensive Income and Shareholders Equity (Tables)

3 Months Ended

Mar. 31, 2018

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in each component of accumulated other comprehensive items, net of tax are as follows: 

(In millions)	Currency Translation Adjustment			Unrealized Losses on Available-for- Sale Investments			Unrealized Losses on Hedging Instruments			Pension and Other Postretirement Benefit Liability Adjustment			Total
Balance at December 31, 2017	$	(1,755	)	$	(1	)	$	(50	)	$	(197	)	$	(2,003	)
Cumulative effect of accounting changes (Note 1)	(54		)	1			(11		)	(24		)	(88		)
Other comprehensive income (loss) before reclassifications	47			—			—			(2		)	45
Amounts reclassified from accumulated other comprehensive items	—			—			2			2			4
Net other comprehensive items	47			—			2			—			49
Balance at March 31, 2018	$	(1,762	)	$	—		$	(59	)	$	(221	)	$	(2,042	)

XML

Fair Value Measurements and Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2018 and December 31, 2017:

	March 31,		Quoted Prices in Active Markets		Significant Other Observable  Inputs		Significant Unobservable Inputs
(In millions)	2018		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	36	$	36	$	—	$	—
Bank time deposits	2		2		—		—
Investments in mutual funds and other similar instruments	13		13		—		—
Warrants	2		—		2		—
Insurance contracts	115		—		115		—
Derivative contracts	7		—		7		—
Total Assets	$	175	$	51	$	124	$	—
Liabilities
Derivative contracts	$	165	$	—	$	165	$	—
Contingent consideration	41		—		—		41
Total Liabilities	$	206	$	—	$	165	$	41

	December 31,		Quoted Prices in  Active Markets		Significant Other Observable  Inputs		Significant  Unobservable  Inputs
(In millions)	2017		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	22	$	22	$	—	$	—
Bank time deposits	2		2		—		—
Investments in mutual funds and other similar instruments	13		13		—		—
Warrants	2		—		2		—
Insurance contracts	116		—		116		—
Derivative contracts	10		—		10		—
Total Assets	$	165	$	37	$	128	$	—
Liabilities
Derivative contracts	$	139	$	—	$	139	$	—
Contingent consideration	35		—		—		35
Total Liabilities	$	174	$	—	$	139	$	35

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]

	Fair Value – Assets				Fair Value – Liabilities
	March 31,		December 31,		March 31,		December 31,
(In millions)	2018		2017		2018		2017
Derivatives Designated as Hedging Instruments
Interest rate swaps (a)	$	—	$	—	$	162	$	124
Derivatives Not Designated as Hedging Instruments
Currency exchange contracts (b)	7		10		3		15
Total Derivatives	$	7	$	10	$	165	$	139

(a) The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities.

(b) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses.

The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations:

	Carrying Amount of the Hedged Liability				Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability (c)
	March 31,		December 31,		March 31,			December 31,
(In millions)	2018		2017		2018			2017
Long-term Obligations	$	3,261	$	3,309	$	(120	)	$	(70	)

(c) Includes increases in the carrying amount of $40 million and $43 million at March 31, 2018 and December 31, 2017, respectively, on discontinued hedging relationships

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]

	Gain (Loss) Recognized
	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Fair Value Hedging Relationships
Interest rate swaps
Hedged long-term obligations - included in other expense, net	$	(38	)	$	(6	)
Derivatives designated as hedging instruments - included in other expense, net	42			3
Derivatives Designated as Cash Flow Hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to other expense, net	(3		)	(3		)
Derivatives Designated as Net Investment Hedges
Foreign currency-denominated debt
Included in currency translation adjustment within other comprehensive items	(200		)	(46		)
Derivatives Not Designated as Hedging Instruments
Currency exchange contracts
Included in cost of revenues	(2		)	(1		)
Included in other expense, net	(8		)	19

Fair Value, by Balance Sheet Grouping [Table Text Block]

The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:

	March 31, 2018				December 31, 2017
	Carrying		Fair		Carrying		Fair
(In millions)	Value		Value		Value		Value
Notes Receivable	$	94	$	99	$	89	$	93
Debt Obligations:
Senior notes	$	19,742	$	20,053	$	20,024	$	20,639
Commercial paper	1,171		1,171		960		960
Other	23		23		24		24
	$	20,936	$	21,247	$	21,008	$	21,623

The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]

The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:

	March 31, 2018				December 31, 2017
	Carrying		Fair		Carrying		Fair
(In millions)	Value		Value		Value		Value
Notes Receivable	$	94	$	99	$	89	$	93
Debt Obligations:
Senior notes	$	19,742	$	20,053	$	20,024	$	20,639
Commercial paper	1,171		1,171		960		960
Other	23		23		24		24
	$	20,936	$	21,247	$	21,008	$	21,623

The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration.

	Three Months Ended
	March 31,			April 1,
(In millions)	2018			2017
Contingent Consideration
Beginning Balance	$	35		$	6
Acquisitions	11			9
Payments	(5		)	—
Change in fair value included in earnings	—			25
Ending Balance	$	41		$	40

XML

Supplemental Cash Flow Information (Tables)

3 Months Ended

Mar. 31, 2018

Supplemental Cash Flow Information [Abstract]

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

	Three Months Ended
	March 31,		April 1,
(In millions)	2018		2017
Non-cash Investing and Financing Activities
Declared but unpaid dividends	$	69	$	60
Issuance of stock upon vesting of restricted stock units	61		34

Restrictions on Cash and Cash Equivalents [Table Text Block]

Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:

	March 31,		December 31,
(In millions)	2018		2017
Cash and Cash Equivalents	$	950	$	1,335
Restricted Cash Included in Other Current Assets	23		24
Restricted Cash Included in Other Assets	2		2
Cash, Cash Equivalents and Restricted Cash	$	975	$	1,361

XML

Restructuring and Other Costs, Net (Tables)

3 Months Ended

Mar. 31, 2018

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs [Table Text Block]

During the first quarter of 2018, the company recorded net restructuring and other costs by segment as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs, Net		Total
Life Sciences Solutions	$	—	$	—	$	13	$	13
Analytical Instruments	—		—		17		17
Specialty Diagnostics	—		—		4		4
Laboratory Products and Services	3		7		10		20
Corporate	—		1		1		2
	$	3	$	8	$	45	$	56

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.

(In millions)	Severance			Abandonment of Excess Facilities			Other (a)			Total
Balance at December 31, 2017	$	30		$	40		$	6		$	76
Costs incurred in 2018 (c)	19			16			4			39
Reserves reversed (b)	(3		)	(1		)	—			(4		)
Payments	(10		)	(8		)	(5		)	(23		)
Balance at March 31, 2018	$	36		$	47		$	5		$	88

(a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

(b) Represents reductions in cost of plans.

(c) Excludes $10 million of charges, net, primarily associated with litigation-related matters, hurricane response costs, and non-cash compensation due at an acquired business.

XML

Contract Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Contract with Customer, Asset and Liability [Abstract]
Current Contract Assets, Net	$ 458	$ 396
Current Contract Liabilities	909	805	$ 0
Noncurrent Contract Liability	317	$ 302
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 308

XML

Warranty Obligations (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Warranty Obligations [Roll Forward]
Beginning Balance	$ 87	$ 78
Provision charged to income	31	25
Usage	(28)	(25)
Acquisitions		1
Adjustments to previously provided warranties, net	(1)	(1)
Currency translation	1	1
Ending Balance	$ 90	$ 79

XML

Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw Materials	$ 776		$ 708
Work in Process	402		505
Finished Goods	1,713		1,758
Inventories	$ 2,891	$ 2,719	$ 2,971

XML

Property, Plant and Equipment (Details) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	$ 6,520	$ 6,339
Less: Accumulated Depreciation and Amortization	2,461	2,292
Property, Plant and Equipment, Net	4,059	4,047
Land [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	405	401
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	1,688	1,662
Machinery, Equipment and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	$ 4,427	$ 4,276

XML

Acquisition-related Intangible Assets (Details) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	$ 25,128	$ 24,974
Accumulated Amortization	(10,020)	(9,564)
Definite-Lived Intangible Assets, Net	15,108	15,410
Indefinite-Lived Intangible Assets	1,285	1,274
Acquisition-related Intangible Assets, Gross	26,413	26,248
Acquisition-related Intangible Assets, net of Accumulated Amortization	16,393	16,684
Tradenames [Member]
Definite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	1,235	1,235
In-Process Research and Development [Member]
Definite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	50	39
Customer Relationships [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	17,439	17,356
Accumulated Amortization	(6,170)	(5,902)
Definite-Lived Intangible Assets, Net	11,269	11,454
Product Technology [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	6,107	6,046
Accumulated Amortization	(2,953)	(2,811)
Definite-Lived Intangible Assets, Net	3,154	3,235
Tradenames [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	1,547	1,538
Accumulated Amortization	(862)	(817)
Definite-Lived Intangible Assets, Net	685	721
Other Intangible Assets [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	35	34
Accumulated Amortization	(35)	(34)
Definite-Lived Intangible Assets, Net	$ 0	$ 0

XML

Recent Accounting Pronouncements (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase in Total Costs and Operating Expenses (principally SG&A Expenses)	$ 5,067	$ 4,145
Decrease in Operating Income	(786)	(620)
Increase in Other Income (Expense)	(152)	(117)
Accounts receivable, less allowances	3,990		$ 3,871	$ 3,879
Inventories	2,891		2,719	2,971
Other current assets	1,217		1,100	804
Other Assets	1,178		1,150	1,227
Contract liabilities	909		805	0
Deferred Revenue	0		0	719
Other accrued expenses	1,352		1,695	1,848
Deferred Income Taxes	2,606		2,711	2,766
Other Long-term Liabilities	2,657		2,623	2,569
Long-term Obligations	18,122		18,870	18,873
Retained earnings	16,542		16,032	15,914
Accumulated other comprehensive items	(2,042)		(2,091)	$ (2,003)
Accounting Standards Update 2017-07 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase in Total Costs and Operating Expenses (principally SG&A Expenses)		2
Decrease in Operating Income		2
Increase in Other Income (Expense)		$ 2
Accounting Standards Update 2016-01 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings			(1)
Accumulated other comprehensive items			1
Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other Assets			(77)
Deferred Income Taxes			(57)
Retained earnings			(20)
Accounting Standards Update 2017-12 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term Obligations			(3)
Retained earnings			3
Accounting Standard Update 2018-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred Income Taxes			2
Retained earnings			87
Accumulated other comprehensive items			(89)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories	(280)
Other current assets	$ 344
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts receivable, less allowances			(8)
Inventories			(252)
Other current assets			296
Contract liabilities			805
Deferred Revenue			(719)
Other accrued expenses			(153)
Other Long-term Liabilities			54
Retained earnings			$ 49

XML

Acquisitions Purchase Price (Details) $ in Millions	3 Months Ended
	Mar. 31, 2018 USD ($)
Other [Member]
Purchase Price
Total Purchase Price	$ 65

XML

Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Disaggregation of Revenue [Line Items]
Product revenues	$ 4,528	$ 4,102
Service revenues	1,325	663
Revenues	5,853	$ 4,765
Revenue, Remaining Performance Obligation	4,940
North America [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,903
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,518
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,264
Other Regions [Member]
Disaggregation of Revenue [Line Items]
Revenues	168
Consumables [Member]
Disaggregation of Revenue [Line Items]
Product revenues	3,111
Instruments [Member]
Disaggregation of Revenue [Line Items]
Product revenues	$ 1,416

XML

Business Segment Information (Details) $ in Millions		3 Months Ended
		Mar. 31, 2018 USD ($) Segment	Apr. 01, 2017 USD ($)
Segment Reporting Information [Line Items]
Number of Reportable Segments | Segment		4
Revenues		$ 5,853	$ 4,765
Cost of revenues charges		(3)
Selling, general and administrative charges, net		(8)
Restructuring and other costs, net		(45)	(24)
Operating Income		786	620
Other expense, net		(152)	(117)
Income from Continuing Operations Before Income Taxes		634	503
Depreciation		131	97
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs, net		(13)
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs, net		(17)
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs, net		(4)
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges		(3)
Selling, general and administrative charges, net		(7)
Restructuring and other costs, net		(10)
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Operating Income	[1]	1,286	1,074
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues		1,499	1,363
Operating Income	[1]	517	433
Depreciation		31	33
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues		1,257	1,052
Operating Income	[1]	246	192
Depreciation		18	17
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues		947	866
Operating Income	[1]	243	233
Depreciation		19	17
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues		2,413	1,699
Operating Income	[1]	280	216
Depreciation		63	30
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues		(263)	(215)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges		(3)	(31)
Selling, general and administrative charges, net		(8)	(31)
Restructuring and other costs, net		(45)	(24)
Amortization of acquisition-related intangible assets		$ (444)	$ (368)

[1] Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

XML

Geographical Information (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2018	Apr. 01, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 5,853	$ 4,765
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	2,756	2,377
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	541	441
All Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 2,556	$ 1,947

[1] Revenues are attributed to countries based on customer location.

XML

Other Expense, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Other Income and Expenses [Abstract]
Interest Income	$ 20	$ 18
Interest Expense	(163)	(135)
Other Items, Net	(9)	0
Other Expense, Net	$ (152)	$ (117)

XML

Income Taxes Rate Reconciliation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory Federal Income Tax Rate	21.00%	35.00%
Provision for Income Taxes at Statutory Rate	$ 133	$ 176
Foreign rate differential	(19)	(84)
Income tax credits	(41)	(41)
Foreign-derived intangible income	(9)
Singapore tax holiday	(8)	(5)
Impact of change in tax laws and apportionment on deferred taxes	3	(63)
Transition tax and other initial impacts of U.S. tax reform	70
Provision of tax reserves, net	(49)
Excess tax benefits from stock options and restricted stock units	(25)	(24)
Other, net		(7)
Provision for (benefit from) income taxes	55	$ (48)
Tax Cuts And Jobs Act of 2017, Income Tax Expense (Benefit)	$ 21
Singapore
Income Tax Holiday [Line Items]
Income Tax Holiday, Termination Date	12/31/2026
Effective Income Tax Rate Reconciliation, Tax Holiday, Percent	1.30%	0.90%
Income Tax Holiday, Income Tax Benefits Per Share	$ 0.02	$ 0.01

XML

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	3 Months Ended
	Mar. 31, 2018 USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of year	$ 1,409
Reductions due to acquisitions	(9)
Additions for tax positions of current year	1
Additions for tax positions of prior years	1
Reductions for tax positions of prior years	(84)
Settlements	(45)
Balance at end of year	$ 1,273

XML

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net Income	$ 579	$ 551
Basic Weighted Average Shares	402	391
Effect of Stock Options and Restricted Units	4	3
Diluted Weighted Average Shares	406	394
Basic Earnings per Share:
Basic Earnings Per Share (in dollars per share)	$ 1.44	$ 1.41
Diluted Earnings per Share:
Diluted Earnings Per Share (in dollars per share)	$ 1.43	$ 1.40
Employee Stock Option [Member]
Diluted Earnings per Share:
Antidilutive Stock Options Excluded From Computation Of Earnings Per Share	2	3

XML

Debt Outstanding Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total Borrowings at Par Value	$ 21,154		$ 21,175
Fair Value Hedge Accounting Adjustments	(120)		(70)
Unamortized Discount, Net	(8)		(2)
Unamortized Debt Issuance Costs	(90)		(95)
Total Borrowings at Carrying Value	20,936		21,008
Less: Short-term Obligations and Current Maturities	2,814		2,135
Long-term Obligations	18,122	$ 18,870	18,873
Commercial Paper Programs [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value	1,171		960
Total Borrowings at Carrying Value	1,171		960
Senior Notes [Member]
Debt Instrument [Line Items]
Total Borrowings at Carrying Value	$ 19,742		20,024
Debt Instrument, Call Feature	Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium plus accrued interest.
Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 8/9/2018 (euro-denominated) [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Aug. 09, 2018
Effective Interest Rate	0.38%
Total Borrowings at Par Value	$ 739		721
Senior Notes [Member] | 2.15% 3-Year Senior Notes, Due 12/14/2018 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.15%
Debt Instrument, Term	3 years
Debt Instrument, Maturity Date	Dec. 14, 2018
Total Borrowings at Par Value			450
Senior Notes [Member] | 2.40% 5-Year Senior Notes, Due 2/1/2019 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.40%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	Feb. 01, 2019
Effective Interest Rate	2.59%
Total Borrowings at Par Value	$ 900		900
Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated) [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Jul. 24, 2019
Effective Interest Rate	0.09%
Total Borrowings at Par Value	$ 616		600
Senior Notes [Member] | 6.00% 10-Year Senior Notes, Due 3/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	6.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 01, 2020
Effective Interest Rate	2.97%
Total Borrowings at Par Value	$ 750		750
Senior Notes [Member] | 4.70% 10-Year Senior Notes, Due 5/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.70%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	May 01, 2020
Effective Interest Rate	4.23%
Total Borrowings at Par Value	$ 300		300
Senior Notes [Member] | 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.50%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	Dec. 01, 2020
Effective Interest Rate	1.62%
Total Borrowings at Par Value	$ 524		510
Senior Notes [Member] | 5.00% 10-Year Senior Notes, Due 1/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Jan. 15, 2021
Effective Interest Rate	3.24%
Total Borrowings at Par Value	$ 400		400
Senior Notes [Member] | 4.50% 10-Year Senior Notes, Due 3/1/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.50%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 01, 2021
Effective Interest Rate	6.24%
Total Borrowings at Par Value	$ 1,000		1,000
Senior Notes [Member] | 3.60% 10-Year Senior Notes, Due 8/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.60%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2021
Effective Interest Rate	6.06%
Total Borrowings at Par Value	$ 1,100		1,100
Senior Notes [Member] | 3.30% 7-Year Senior Notes, Due 2/15/2022 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.30%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Feb. 15, 2022
Effective Interest Rate	3.43%
Total Borrowings at Par Value	$ 800		800
Senior Notes [Member] | 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.15%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Jul. 21, 2022
Effective Interest Rate	2.28%
Total Borrowings at Par Value	$ 616		600
Senior Notes [Member] | 3.15% 10-Year Senior Notes, Due 1/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Jan. 15, 2023
Effective Interest Rate	3.30%
Total Borrowings at Par Value	$ 800		800
Senior Notes [Member] | 3.00% 7-Year Senior Notes, Due 4/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.00%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2023
Effective Interest Rate	6.23%
Total Borrowings at Par Value	$ 1,000		1,000
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Feb. 01, 2024
Effective Interest Rate	4.16%
Total Borrowings at Par Value	$ 1,000		1,000
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.75%
Debt Instrument, Term	8 years
Debt Instrument, Maturity Date	Sep. 12, 2024
Effective Interest Rate	0.95%
Total Borrowings at Par Value	$ 1,232		1,201
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Apr. 15, 2025
Effective Interest Rate	2.10%
Total Borrowings at Par Value	$ 789		768
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.65%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Effective Interest Rate	3.77%
Total Borrowings at Par Value	$ 350		350
Senior Notes [Member] | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.40%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Jan. 23, 2026
Effective Interest Rate	1.53%
Total Borrowings at Par Value	$ 863		840
Senior Notes [Member] | 2.95% 10-Year Senior Notes, Due 9/19/2026 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.95%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Sep. 19, 2026
Effective Interest Rate	3.19%
Total Borrowings at Par Value	$ 1,200		1,200
Senior Notes [Member] | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.45%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 16, 2027
Effective Interest Rate	1.67%
Total Borrowings at Par Value	$ 616		600
Senior Notes [Member] | 3.20% 10-Year Senior Notes, Due 8/15/2027 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.20%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2027
Effective Interest Rate	3.39%
Total Borrowings at Par Value	$ 750		750
Senior Notes [Member] | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Sep. 12, 2028
Effective Interest Rate	1.46%
Total Borrowings at Par Value	$ 739		721
Senior Notes [Member] | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.95%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Jul. 24, 2029
Effective Interest Rate	2.08%
Total Borrowings at Par Value	$ 863		840
Senior Notes [Member] | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.875%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Jul. 24, 2037
Effective Interest Rate	2.94%
Total Borrowings at Par Value	$ 863		840
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.30%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Feb. 01, 2044
Effective Interest Rate	5.37%
Total Borrowings at Par Value	$ 400		400
Senior Notes [Member] | 4.10% 30-Year Senior Notes, Due 8/15/2047 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.10%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Aug. 15, 2047
Effective Interest Rate	4.32%
Total Borrowings at Par Value	$ 750		750
Other Debt [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value	23		24
Total Borrowings at Carrying Value	$ 23		$ 24

XML

Debt Short-term Financing (Details)	3 Months Ended
	Mar. 31, 2018 USD ($)
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA	4.0
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA, Beginning in the Third Quarter 2018	3.5
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3
Maximum Borrowing Capacity	$ 2,500,000,000
Line of Credit Facility, Expiration Date	Jul. 01, 2021
Letters of Credit Outstanding, Amount	$ 75,000,000
Line of Credit Facility, Amount Outstanding	$ 0
Commercial Paper Programs [Member]
Short-term Financing [Line Items]
Short-term Debt, Period to Maturity	50 days
Commercial Paper Programs [Member] | U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Commercial Paper Programs [Member] | Euro Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	183 days

XML

Debt, Interest Rate Swap Arrangements (Details) - Interest Rate Swaps [Member] - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Notional Amount Of Derivatives	$ 3,100	$ 3,100
Senior Notes [Member] | 4.50% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR	3.442%
Interest Rate Swap, Pay Rate at Period End	5.1062%
Interest Rate Swap, Fixed Receive Rate	4.50%
Senior Notes [Member] | 3.60% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	$ 1,100
Interest Rate Swap, Pay Rate Spread above One-month LIBOR	2.515%
Interest Rate Swap, Pay Rate at Period End	4.2916%
Interest Rate Swap, Fixed Receive Rate	3.60%
Senior Notes [Member] | 3.00% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR	1.764%
Interest Rate Swap, Pay Rate at Period End	3.5406%
Interest Rate Swap, Fixed Receive Rate	3.00%

XML

Commitments and Contingencies (Details) - USD ($) $ in Millions	Feb. 03, 2014	Mar. 31, 2018
Accrual for Environmental Loss Contingencies Disclosure [Abstract]
Accrual for Environmental Loss Contingencies, Net		$ 61
Promega Corp and Max-Plank-Gesellschaft [Member]
Loss Contingency [Abstract]
Loss Contingency Accrued		$ 52
Promega Corp and Max-Plank-Gesellschaft [Member] | Life Technologies Corporation [Member]
Loss Contingency [Abstract]
Damages Awarded	$ 52
Loss Contingency Accrued	$ 52

XML

Comprehensive Income and Shareholders' Equity (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 25,413	$ 21,540
Cumulative effect of accounting changes			$ 30
Other comprehensive income (loss) before reclassifications	45
Amounts reclassified from accumulated other comprehensive items	4
Total other comprehensive items	49	163
Balance	26,123	21,795
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(1,755)
Cumulative effect of accounting changes			(54)
Other comprehensive income (loss) before reclassifications	47
Total other comprehensive items	47
Balance	(1,762)
Unrealized Gains on Available-for-Sale Investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(1)
Cumulative effect of accounting changes			1
Total other comprehensive items	0
Balance	0
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(50)
Cumulative effect of accounting changes			(11)
Amounts reclassified from accumulated other comprehensive items	2
Total other comprehensive items	2
Balance	(59)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(197)
Cumulative effect of accounting changes			(24)
Other comprehensive income (loss) before reclassifications	(2)
Amounts reclassified from accumulated other comprehensive items	2
Total other comprehensive items	0
Balance	(221)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,003)	(2,636)
Cumulative effect of accounting changes			$ (88)
Total other comprehensive items	49	163
Balance	$ (2,042)	$ (2,473)

XML

Fair Value Measurements, Assets and Liabilities (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Assets [Abstract]
Cash equivalents	$ 36	$ 22
Bank time deposits	2	2
Investments in mutual funds and other similar instruments	13	13
Warrants	2	2
Insurance contracts	115	116
Derivative contracts	7	10
Total Assets	175	165
Liabilities [Abstract]
Derivative contracts	165	139
Contingent consideration	41	35
Total Liabilities	206	174
Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	36	22
Bank time deposits	2	2
Investments in mutual funds and other similar instruments	13	13
Total Assets	51	37
Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	2	2
Insurance contracts	115	116
Derivative contracts	7	10
Total Assets	124	128
Liabilities [Abstract]
Derivative contracts	165	139
Total Liabilities	165	139
Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	41	35
Total Liabilities	$ 41	$ 35

XML

Fair Value Measurements and Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 35	$ 6
Acquisitions	11	9
Payments	(5)
Change in fair value included in earnings		25
Ending Balance	$ 41	$ 40

XML

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	$ (120)	$ (70)
Long-term Obligations [Member]
Derivatives, Fair Value [Line Items]
Hedged Liability, Fair Value Hedge	3,261	3,309
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	(120)	(70)
Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)	40	43
Interest Rate Swaps [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	3,100	3,100
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value	162	124
Currency Exchange Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	2,980	2,920
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value	7	10
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value	3	15
Fair Value, Measurements, Recurring [Member]
Derivatives, Fair Value [Line Items]
Total Derivative Assets	7	10
Total Derivative Liabilities	$ 165	$ 139

XML

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	$ (200)	$ (46)
Currency Exchange Contracts [Member] | Cost of Sales [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	(2)	(1)
Currency Exchange Contracts [Member] | Other Expense [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	(8)	19
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Expense [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Hedged Debt in Fair Value Hedge	(38)	(6)
Gain (Loss) on Derivative, Net	42	3
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Expense [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax	$ (3)	$ (3)

XML

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes Receivable - Carrying Value	$ 94	$ 89
Notes Receivable - Fair Value	99	93
Debt Obligations - Carrying Value	20,936	21,008
Debt Instrument, Fair Value Disclosure	21,247	21,623
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	19,742	20,024
Debt Instrument, Fair Value Disclosure	20,053	20,639
Commercial Paper Programs [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	1,171	960
Debt Instrument, Fair Value Disclosure	1,171	960
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	23	24
Debt Instrument, Fair Value Disclosure	$ 23	$ 24

XML

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Apr. 01, 2017	Dec. 31, 2017	Dec. 31, 2016
Non-cash Investing and Financing Activities [Abstract]
Declared but unpaid dividends	$ 69	$ 60
Issuance of stock upon vesting of restricted stock units	61	34
Cash and Cash Equivalents	950		$ 1,335
Restricted Cash Included in Other Current Assets	23		24
Restricted Cash Included in Other Assets	2		2
Cash, Cash Equivalents and Restricted Cash	$ 975	$ 737	$ 1,361	$ 811
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsCurrent
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent

XML

Restructuring and Other Costs, Net (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2018	Apr. 01, 2017	May 04, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated, Less than		1.00%
Cost of Revenues		$ 3
Selling, General and Administrative Expenses		8
Restructuring and Other Costs, Net		45	$ 24
Total Restructuring and Other Costs (Income), Net		56
Restructuring and Related Costs, Cash Costs	[1]	39
Restructuring and Related Costs, Other Costs (Income), Net		10
Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs		19
Abandonment of Excess Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs		16
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	[2]	4
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Other Costs, Net		13
Total Restructuring and Other Costs (Income), Net		13
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Other Costs, Net		17
Total Restructuring and Other Costs (Income), Net		17
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Other Costs, Net		4
Total Restructuring and Other Costs (Income), Net		4
Laboratory Products and Services [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		3
Selling, General and Administrative Expenses		7
Restructuring and Other Costs, Net		10
Total Restructuring and Other Costs (Income), Net		20
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		1
Restructuring and Other Costs, Net		1
Total Restructuring and Other Costs (Income), Net		$ 2
Scenario, Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs				$ 105

[1] Excludes $10 million of charges, net, primarily associated with litigation-related matters, hurricane response costs, and non-cash compensation due at an acquired business.

[2] Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

XML

Restructuring Reserves (Details) $ in Millions	3 Months Ended
	Mar. 31, 2018 USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 76
Costs incurred	39	[1]
Reserves reversed	(4)	[2]
Payments	(23)
Ending balance	88
Restructuring and Related Costs, Other Costs (Income), Net	10
Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	30
Costs incurred	19
Reserves reversed	(3)	[2]
Payments	(10)
Ending balance	$ 36
Restructuring Reserve, Expected Final Year of Payments	2018
Abandonment of Excess Facilities [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	$ 40
Costs incurred	16
Reserves reversed	(1)	[2]
Payments	(8)
Ending balance	$ 47
Restructuring Reserve, Expected Final Year of Payments	2027
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	$ 6	[3]
Costs incurred	4	[3]
Payments	(5)	[3]
Ending balance	$ 5	[3]

[1] Excludes $10 million of charges, net, primarily associated with litigation-related matters, hurricane response costs, and non-cash compensation due at an acquired business.

[2] Represents reductions in cost of plans.

[3] Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.